SERUM AMYLOID A IN RUMINANTS: DIAGNOSTIC VALUE AND FOOD CONTAMINATION ASSESSMENT by L.F. Pisani
 - 1 - 
 
 
 
 
 
DIPARTIMENTO DI PATOLOGIA ANIMALE, IGIENE E SANITÀ PUBBLICA VETERINARIA 
 
Corso di Dottorato in Igiene Veterinaria e Patologia Animale 
CICLO XXIII 
aa 2007 - 2010 
 
 
Tesi di Dottorato di Ricerca 
For the degree of Doctor of Philosophy 
 
 
Serum Amyloid A in ruminants:  
diagnostic value and food contamination assessment    
Vet/03 - Patologia Generale e Anatomia Patologica Veterinaria 
 
 
Laura Francesca PISANI 
R07456 
 
 
TUTOR: Prof.ssa Paola SARTORELLI 
COORDINATORE DEL DOTTORATO: Prof. Claudio GENCHI 
 
 - 2 - 
 
 
 
 
 
 
 
 
 
Dubium sapientiae initium 
(René Descartes) 
 
 
 
 
 
 
 
 
 
 
 - 3 - 
 
Contents 
Abstract 6 
1. Chapter 1. Introduction to the thesis: the systemic reaction of 
inflammation and the acute phase proteins 
7 
1.1. Inflammation 7 
1.1.1  Acute Phase Proteins and other systemic responses to inflammation 12 
1.2. Biological functions of APPs 15 
1.3. APPs in veterinary medicine 17 
1.4. Serum Amyloid A (SAA) 18 
1.5. SAA structure and expression 19 
1.5.1  Gene 19 
1.5.2  Protein 21 
1.5.3  Hepatic and extrahepatic production of SAA 23 
1.6. SAA functions and disease association 26 
1.6.1  Immune-related functions 26 
1.6.2  Lipid-related functions 26 
1.6.3  Anti-inflammatory roles 27 
1.6.4  SAA and Amyloidosis 28 
1.7. Bovine SAA 30 
1.8. Aims of the thesis 31 
2. Chapter 2. Acute Phase Response in Water Buffaloes 32 
2.1   Introduction 32 
2.1.1   Water buffalo in Italy 32 
2.1.2   What is mastitis? 33 
2.1.3   Bovine and Water buffalo mastitis 34 
 - 4 - 
 
2.1.4   Mammary gland immunology 36 
2.1.5   Current approaches for diagnoses of mastitis 38 
2.1.6   Acute Phase Proteins and mastitis 40 
2.2   Material and Methods 41 
2.2.1   Samples 41 
2.2.2   Bacteriological procedures 41 
2.2.3   Determination of Somatic cells counts (SCC) 42 
2.2.4   Testing the cross-reactivity of the commercially available assays in water 
buffalo 
42 
2.2.5   Quantification of SAA in serum and milk 43 
2.2.6   Quantification of AGP in serum 43 
2.2.7   Statistical analysis 44 
2.2.8     Determination of primary structure of Ceruloplasmin, Haptoglobin, α1 
acid glycoprotein, Serum amyloid A and Lipopolysaccharide binding 
protein 
44 
2.3  Results 46 
2.3.1    Bacteriological procedures 46 
2.3.2    Determination of Somatic cells counts (SCC) 46 
2.3.3    Assessment of the cross-reactivity of immunological assays for acute 
phase proteins 
48 
2.3.4    Acute Phase Protein concentration measurement in serum and milk 49 
2.3.5    Acute Phase Protein sequencing 51 
2.4   Discussion 53 
3. Chapter 3. Study on the possible presence of amyloid (AA) in dairy 
products 
55 
3.1   Introduction 55 
3.1.1  Conformational diseases and Amyloidosis 55 
 - 5 - 
 
3.1.2   Systemic amyloidoses 58 
3.1.3   Amyloidosis in cattle 61 
3.1.4   Transmissibility of systemic amyloidosis 61 
3.2   Materials and Methods 65 
3.2.1   Samples and histological diagnoses of amyloidosis 65 
3.2.2   AA fibrils purification 65 
3.2.3   Quantification of fibrils 65 
3.2.4   SDS-PAGE, Western Blotting and Comassie Brilliant Blue Staining 66 
3.2.5   Experimental cheese making 66 
3.2.6   Extraction of fibrils from cheese 67 
3.2.7   SDS-PAGE and Western Blotting 67 
3.3   Results 68 
3.3.1   Morphology and histology of bovine spleen and kidney 68 
3.3.2   Purification, quantification and analysis of fibrils extracted from tissue 68 
3.3.3   Experimental cheese 70 
3.3.4   Purification and analysis of fibrils extracted from cheese 70 
3.4   Discussion 71 
4. Chapter 4. Conclusions & Final Remarks 74 
5. References  75 
6. Publications 84 
 
 
 
 
 
 - 6 - 
 
Abstract 
 
The aims of the work presented in this thesis were to investigate the bovine acute phase 
protein Serum Amyloid A, focussing on its value as safety marker in farm animals.  
 
SAA can be considered as a natural anti-inflammatory and immunomodulatory agent and local 
expression of SAA, at the site of the initial acute phase reaction, could protect against the 
deleterious effects of inflammation. 
 
In this study whether SAA can be isolated from tissues of bovine with clinical amyloidosis was 
investigated. We also investigated if AA fibrils present in milk can be then found in cheese after 
caseification, i.e. if the process of ripeining can degrade the AA fibrils.  
 
In bovine, SAA was identified as potential marker of mastitis, and SAA milk concentration in 
milk increases before the raising of somatic cells.  
 
In this thesis two aspects of the involvement of SAA in food safety were explored: 
a) the acute phase reaction strongly focused on the mammary gland. The animal model 
chosen was water buffalo, since no information is available so far about the acute 
phase reaction in this species. The acute phase proteins sequences are unknown, and 
also their concentration in physiological and pathological conditions are not 
established.  
b) The possibility that high concentration of SAA in milk induce the formation of amyloid 
fibrils, which are considered to be potentially dangerous for human safety.  
 
Results presented in this thesis advanced the knowledge of the acute phase reaction in water 
buffalo: the five APPs included in this investigation, namely Serum amyloid A, Haptoglobin, 
Ceruloplasmin, α1-acid glycoprotein and Lipolysaccaride Binding Protein were sequenced for 
the first time, and two of them were quantified.  
In the second part of the thesis, we purified amyloid fibryls from amyloidosis-affected cows, 
and added purified fibrils at a given concentration in milk before ripening.  
Results demonstrated the presence of insoluble fibrils in cheese added with amyloid proteins, 
even if a lower amount of precipitated insoluble SAA could be detected also in negative control 
cheese. 
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Chapter 1 
 
Introduction to the thesis  
 
The systemic reaction of inflammation and the acute phase proteins 
 
1.1  Inflammation 
Inflammation is a defensive response that enables survival during infection or injury and 
maintains tissue homeostasis under a variety of noxious conditions.  
Inflammation has been known to humankind for thousand years, in part because it 
accompanied two major scourges of the past, wounds and infections, and in part because it is 
rather conspicuous. Although references to inflammation can be found in ancient medical 
texts, apparently the first to define its clinical symptoms was the Roman doctor Cornelius 
Celsus in the 1st century AD. These symptoms came to be known as the four cardinal signs of 
inflammation: “Notae vero inflammationis sunt quattuor: rubor et tumor cum calore et dolore”. 
Celsus mentions these signs in his treatise De medicina, while describing procedures for 
treating chest pain (Majno, 1975). The fifth cardinal sign, functio laesa, was added by Galen in 
3rd century AD and restates by Rudolph Virchow in 1858 in his book Cellularpathologie a 
collection of lectures published in 1858, which was instantly accepted as the cornerstone of 
modern pathology: “Nobody would expect a muscle which is inflamed, to perform is function 
normally...Now there can be no doubt that to the four characteristics symptoms of 
inflammation functio laesa must be added” (Majno, 1975).  
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Advances in microscopy and cell biology in the 19th century gave rise to cell based definitions 
of inflammation. This represented a completely novel way of understanding and defining 
inflammation. By the end of the 19th century it was acknowledged that changing cell 
populations arising from both the blood and local proliferation were a key feature of many 
models of inflammation (Cotran, 1999). With the advent of the microscope, such a complexity 
of events underlying inflammatory reactions was revealed that researchers began to question 
whether inflammation was indeed a single process (Table 1.1).  
 
AUTHOR, YEAR QUOTATION MODERN SIGNIFICANCE 
Celsus, 1
st
 century AD Rubor et tumor cum calore et dolore Emphasised the importance of  clinical 
observations rather than philosophy based 
medicine 
Galen, 3
rd 
century AD pus bonus et laudabilis  – functio lesa Inflammation was seen as an expression of 
humoral theory well into the 19
th
 century 
Virchow, 1858 The inflammatory reaction is a 
consequence of an excessive intake by 
interstitial cells, of food…filtering through 
the vessel wall 
Recognised cellular nature of inflammatory 
response 
Cohnheim, 1873 Finally…there lies outside the vessel…a 
colorless blood corpuscle 
First description of diapedesis 
Metchnikoff, 1908 The primum movens of the inflammatory 
reaction is a digestive action…toward the 
noxious agent 
First to express the view that phagocytes 
were protective, not pathological 
Lewis, 1927 Triple response to injury First recognition of neurogenic inflammation; 
first physiological characterisation of vascular 
events 
Rocha & Silva, 1974 Multi-mediated phenomenon, of a 
pattern type in which all mediators would 
come and go at the appropriate 
moment…increasing vascular 
permeability, attracting leucocytes, 
producing pain, local edema and necrosis 
Biochemical definition of inflammation 
Table 1.1. Key advances in developing a definition of inflammation between 1
st
 and 20
th
 centuries AD (Scott 2004) 
 
Inflammation is an adaptive response that is triggered by noxious stimuli and conditions, such 
as infection and tissue injury (Majno et al 2004; Kumar et al 2003). Inflammation is 
fundamentally a protective response, the ultimate goal of which is to rid the organism of both 
initial cause of cell injury and the consequences of such injury. At the site of invasion by a 
microorganism and the place of tissue injury a number of responses of the tissue itself are 
initiated. During repair the injured tissue is replaced by regeneration of native parenchymal 
cells, by filling of the defect with fibroblastic tissue or by a combination of these two 
processes. The inflammatory response occurs in the vascularised connective tissue, including 
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plasma, circulating cells, blood vessels, cellular and extra-cellular constituents of connective 
tissue. If this delicate balance between inflammation and resolution becomes deregulated, 
inflammation can lead to disease. 
 
Local inflammation is divided into acute (angioflogosis) and chronic (histoflogosis). Systemic 
inflammation, also called acute phase response (APR), can also occur. It is defined as “a 
prominent systemic reaction of the organism to local or systemic disturbances in its 
homeostasis caused by infection, tissue injury, trauma or surgery, neoplastic growth or 
immunological disorders” (Gordon & Koy, 1985; Gruys et al., 1999). 
At a local level, the acute inflammatory response triggered by infection or tissue injury involves 
the coordinated delivery of blood components (plasma and leukocytes) to the site of infection 
or injury (Majno, 2004; Kumar, 2003). This response has been characterized best for microbial 
infections (particularly bacterial infections), in which it is triggered by receptors of the innate 
immune system, such as Toll-like receptors (TLRs) and NOD (nucleotide-binding 
oligomerization-domain protein)-like receptors (NLRs) (Barton, 2008). This initial recognition of 
infection is mediated by tissue resident macrophages and mast cells, leading to the production 
of a variety of inflammatory mediators, including chemokines, cytokines, vasoactive amines, 
eicosanoids and products of proteolytic cascades.  
The main and most immediate effect of these mediators is to elicit a local inflammatory 
exudate: plasma proteins and leukocytes (mainly neutrophils) that are normally restricted to 
the blood vessels now gain access to the extravascular tissues at the site of infection. The 
activated endothelium of the blood vessels allows selective extravasation of neutrophils while 
preventing the exit of erythrocytes. This selectivity is afforded by the inducible ligation of 
endothelial-cell selectins with integrins and chemokine receptors on leukocytes (Pober & 
Sessa, 2007). When they reach the afflicted tissue site, neutrophils become activated, either by 
direct contact with pathogens or through the actions of cytokines secreted by tissue-resident 
cells. Moreover, the neutrophils try to kill the invading agents by releasing the toxic contents 
of their granules, which include reactive oxygen species (ROS) and reactive nitrogen species, 
proteinase 3, cathepsin G and elastase (Nathan, 2006). These highly potent effectors do not 
discriminate between microbial and host targets. Therefore, collateral damages to host tissues 
are unavoidable (Nathan, 2002). A successful acute inflammatory response results in the 
elimination of the infectious agents followed by a resolution and repair phase, which is 
mediated mainly by tissue-resident and recruited macrophages (Serhan & Savill, 2005). The 
switch in lipid mediators from pro-inflammatory prostaglandins to lipoxins, which are anti-
inflammatory, is crucial for the transition from inflammation to resolution. Lipoxins inhibit the 
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recruitment of neutrophils and, instead, promote the recruitment of monocytes, which 
remove dead cells and initiate tissue remodelling (Serhan & Savill, 2005). Resolvins and 
protectins, which constitute another class of lipid mediator, as well as transforming growth 
factor-β and growth factors produced by macrophages, also have a crucial role in the 
resolution of inflammation, including the initiation of tissue repair (Serhan & Savill, 2005; 
Serhan, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The acute phase response. (Cray, 2009). 
 
If the injurious agent cannot be quickly eliminated, the result may be chronic inflammation. 
Chronic inflammation is a prolonged process where active inflammation, tissue destruction 
and attempt at healing may all proceeding simultaneously. Considerable progress has been 
made in understanding the cellular and molecular events that are involved in the acute 
inflammatory response. On the contrary, the events that lead to local chronic inflammation, 
particularly in chronic infections and autoimmune diseases, are still partially understood. Much 
less is known, however, about the causes and mechanisms of systemic chronic inflammation, 
which occurs in a wide variety of diseases, such as, for example, type 2 diabetes and 
cardiovascular diseases. Therefore, given that inflammation not only is beneficial but also can 
be damaging if prolonged, it is not surprising that the entire process is tightly regulated 
(Fig.1.2) 
 - 11 - 
 
 
Figure 1.2. Causes, and physiological and pathological outcomes of inflammation. Depending on the trigger, the 
inflammatory response has a different physiological purpose and pathological consequences. Of the three possible 
initiating stimuli, only infection-induced inflammation is coupled with the induction of an immune response 
(Medzhitov, 2008). 
 
 
The inflammatory response is coordinated by a large range of mediators that form complex 
regulatory networks. They activate specialized sensors, which then elicit the production of 
specific sets of mediators. The mediators, in turn, alter the functional states of tissues and 
organs in a way that allows them to adapt to the conditions indicated by the particular inducer 
of inflammation. Thus, a generic inflammatory pathway consists of inducers, sensors, 
mediators and effectors, with each component determining the type of inflammatory response 
(Fig. 1.3).  
 
 
Figure 1.3. The inflammatory pathway consists of inducers, sensors, mediators, and target tissues. Inducers initiate 
the inflammatory response and are detected by sensors. Sensors are expressed on specialized sentinel cells and 
they induce the production of mediators. These inflammatory mediators act on various target tissues to elicit 
changes in their functional states that optimize adaptation to the noxious condition associated with the particular 
inducers that elicited the inflammatory response. (Medzhitov, 2010). 
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1.1.1  Acute Phase Proteins and other systemic responses to inflammation 
 
A large number of changes, distant from the site or sites of inflammation and involving many 
organ systems, may accompany inflammation. These systemic changes have previously been 
referred to as the acute-phase response, even though they accompany both acute and chronic 
inflammatory disorders (Kushner, 1993). 
Acute-phase changes may be divided into changes in the concentrations of many plasma 
proteins, known as the acute-phase proteins, and a large number of behavioural, physiologic, 
biochemical, and nutritional changes (Table 1.2).  
 
NEUROENDOCRINE 
CHANGES 
HEMATOPOIETI
C CHANGES 
METABOLIC 
CHANGES 
HEPATIC CHANGES CHANGES IN 
NONPROTEIN PLASMA 
CONSTITUENTS 
Fever, somnolence, 
and anorexia 
 
Anemia of  
chronic disease 
 
Loss of muscle and 
negative nitrogen 
balance 
Increased 
metallothionein, 
inducible nitric 
oxide synthase,  
heme oxygenase, 
manganese 
superoxide 
dismutase, and  
tissue inhibitor of 
metalloproteinase1 
Hypozincemia, 
hypoferremia, and 
hypercupremia 
 
Decreased production 
of insulin-like growth 
factor I 
Leukocytosis Osteoporosis Decreased 
phosphoenolpyruva
te carboxykinase 
activity 
Increased plasma 
retinol and glutathione 
concentrations 
Increased secretion of 
corticotropin-
releasing hormone,  
corticotropin, and 
cortisol 
Thrombocytosis Increased hepatic 
lipogenesis 
Increased lipolysis 
in adipose tissue 
  
Increased secretion of 
arginine vasopressin 
 
 Decreased 
lipoprotein lipase 
activity in muscle 
and adipose 
tissue 
  
Increased adrenal 
secretion of 
catecholamines 
 Decreased 
gluconeogenesis 
Cachexia 
  
Table 1.2.  Acute Phase responses (modified from Gabay & Kushner 1999). 
 
The acute phase proteins (APPs) are a group of blood proteins considered to be non-speciﬁc 
innate immune components involved in the restoration of homeostasis and the restraint of 
microbial growth before animals develop acquired immunity to a challenge. APPs plasma 
concentration increases (positive acute-phase proteins) or decreases (negative acute-phase 
proteins) by at least 25% during inflammatory disorders. In any given species, particular APPs 
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demonstrate major, moderate or minor responses. A major APP “responder” has a low serum 
concentration (<1 mg/l) in healthy animals that rises dramatically by 100–1000-fold on 
stimulation, peaking at 24–48 hours and then declining rapidly during the recovery phase. 
Moderate responders increase some 5–10-fold on activation, peak after 2–3 days, and 
decrease more slowly than major APP “responder”. A minor APP responder gradually increases 
by between 50% and 100% of its resting level. ”Negative” APP biomarkers, which fall in 
concentration during the inﬂammatory response, have also been identiﬁed, although except 
for albumin, their use in veterinary clinical pathology is not common (Eckersaal & Bell, 2010). 
The positive APP are glycoproteins synthesized mainly by hepatocytes upon stimulation by 
pro-inﬂammatory cytokines and released into the bloodstream. The positive APP include 
haptoglobin (Hp), C-reactive protein (CRP), serum amyloid A (SAA), caeruloplasmin (Cp), 
ﬁbrinogen (Fb) and alpha 1-acid glycoprotein (AGP). The negative APP include albumin, the 
most abundant constitutive plasma protein, and transferrin.  
Conditions that commonly lead to substantial changes in the plasma concentrations of acute-
phase proteins include infection, trauma, surgery, burns, tissue infraction, various 
immunologically mediated and crystal-induced inflammatory conditions, and advanced cancer. 
Moderate changes occur after strenuous exercise, heatstroke, and childbirth. Small changes 
occur after psychological stress and in several psychiatric illnesses (Gabay & Kushner, 1999) 
(Fig. 1.4). 
 
 
Figure 1.4. Characteristic Patterns of Change in Plasma Concentrations of Some Acute-Phase Proteins after a 
Moderate Inflammatory Stimulus (Gabay et al. 1999) 
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Extrahepatic productions of APP have also been described in most of the mammalian species 
that have been studied so far (Uhlar and Whitehead, 1999; Vreugdenhil et al., 1999). Among 
the proinﬂammatory cytokines, interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha) 
and interleukin-1-beta (IL-1-β) are the major mediators of APP synthesis in the liver 
(Nakagawa-Tosa et al., 1995; Alsemgeest et al., 1996; Yoshioka et al., 2002). These cytokines 
are released mainly by macrophages but also by other cells in response to various external or 
internal stimuli. For example, IL-6 can be synthesized by Kupﬀer cells and keratinocytes 
(Heinrich et al., 1990), in the pituitary (Abraham & Minton, 1997) or in the mucosal epithelium 
(Pritts et al., 2002). Inﬂammation, infection or tissue injury triggers cytokine release by 
defence-oriented cells, thereby inducing APP synthesis. The induction is associated with a 
decrease in synthesis of negative APP such as albumin (Gruys et al., 1994). It is widely accepted 
that, in humans and experimental animals, physical and psychological stress elevates plasma 
IL-6 and APP levels (Deak et al., 1997; Nukina et al., 2001). There is also evidence in cattle that 
physical stress can induce APP (Murata & Miyamoto, 1993; Alsemgeest et al., 1995). Although 
the mechanism of APP induction in response to stress is yet to be elucidated, activation of the 
hypothalamic–pituitary–adrenal (HPA) axis by stress signals may be a trigger of systemic or 
local (intra-pituitary) cytokine production, thereby augmenting hepatic APP synthesis and 
release into the bloodstream. APP levels also increase in healthy cows, mares or dogs at 
parturition (Yamashita et al., 1991; Taira et al., 1992; Alsemgeest et al., 1993; Uchida et al., 
1993; Vannucchi et al., 2002), in cows with hepatic lipidosis (Yoshino et al., 1992; Nakagawa et 
al., 1997), or in fasted cows following dexamethasone administration (Yoshino et al., 1993), 
possibly as a result of hepatic APP production in response to glucocorticoids or oestradiol 
(Higuchi et al., 1994). Glucocorticoids, which are synthesized through the HPA-axis, act to 
suppress pro-inﬂammatory cytokines and up-regulate anti-inﬂammatory cytokines (Bethin et 
al., 2000). Thus the HPA-axis contributes to the modulation of APP synthesis. Conversely, 
cytokines modulate glucocorticoid production by the HPA-axis. For example, IL-6 stimulates 
the HPA-axis and induces augmented adrenal function, which in turn suppresses cytokine 
production by negative feedback (Bethin et al., 2000). This network of induction and regulation 
of APP synthesis is shown in Fig. 1.5. In such a complicated but precise regulation network, the 
APP play an important role in a variety of defence-related activities such as killing infectious 
microbes, repair of tissue damage and restoration of the healthy state. 
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Figure 1.5. Induction and regulation network of acute phase protein (APP) synthesis in animals subjected to internal 
or external challenge (Murata et al., 2004). 
 
1.2  Biological functions of APPs 
The assumption that the changes in plasma concentrations of acute-phase proteins are 
beneficial is based largely on the known functional capabilities of the proteins and on logical 
speculation as to how these might serve useful purposes in inflammation, healing, or 
adaptation to a noxious stimulus. The function of most APPs has not been definitely 
elucidated. The positive APPs are regarded as having general functions in opsonization and 
trapping of microrganisms and their products, in activating complement, in binding cellular 
remnants like nuclear debris, in neutralizing enzymes, scavenging free haemoglobin and 
radicals, and in modulating the host’s immune response (Uhlar & Whitehead, 1999; 
Vreugdenhil et al., 1999, Lecchi et al., 2008).  
C-reactive protein (CRP) plays important roles in protection against infection, clearance of 
damaged tissue, prevention of autoimmunization and regulation of the inﬂammatory response 
(Mold et al., 2002). Is structurally conformed as a ring consisting of five 23KDa units (Volanakis, 
2001) and is the first described APP (Tillett & Francis, 1930). It was discovered due to its 
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binding to the C-polysaccharide of pneumococci. It binds directly to several microorganisms, 
degenerating cells and cell remnants, activates complement by the classical C1q pathway and 
acts as opsonin. CRP interacts also with specific receptors on phagocytic cells to mediate 
phagocytosis and induces the production of anti-inflammatory cytokines, linking non-specific 
innate immunity with specific adaptive immunity (Du Clos & Mold, 2001).  
Serum Amyloid A (SAA): see below. 
Alpha 1-acid glycoprotein (AGP) is a sialo-glycoprotein synthesized and secreted mainly by 
hepatocytes. Extrahepatic AGP production and gene expression have also been conﬁrmed 
(Fournier et al., 2000; Lecchi et al., 2009). Local AGP may contribute to the maintenance of 
homeostasis by reducing the tissue damage associated with the inﬂammatory process taking 
place in extrahepatic cell types, notably epithelial and endothelial cells. Systemic AGP has two 
major physiological functions: drug binding and immunomodulation. concentration. AGP is a 
natural anti-inﬂammatory agent, in that AGP inhibits neutrophil activation and increases the 
secretion of IL-1 receptor antagonist by macrophages (Fournier et al., 2000). AGP may help to 
enhance the clearance of lipopolysaccharide (LPS) by binding directly with LPS and neutralizing 
its toxicity (Moore et al., 1997). AGP also inhibits mitogen-induced lymphocyte proliferation 
(Itoh et al., 1989) and natural killer cell activity (Okumura et al., 1985).  
Haptoglobin (Hp) strongly binds haemoglobin, has anti-inflammatory capabilities and binds to 
CD11b/CD18 integrines (El Ghmati et al., 1996) which are major receptors on the cell 
membranes of leukocytes. Although representing a positive APP, its concentration may 
decrease on massive erythrolysis and when blood is haemolytic, therefore the determination 
by haemoglobin binding assays may give unreliable results. 
Ceruloplasmin (Cp) is a copper-containing ferroxidase that oxidizes toxic ferrous iron to its non-
toxic ferric form. Cp promotes iron loading onto transferrin, which only binds the ferric form of 
the metal. In addition, Cp is an effective antioxidant, because of its ability to oxidize highly 
toxic ferrous iron to the relatively nontoxic ferric form and thus help prevent oxidative damage 
to proteins, lipids, and DNA (Inoue et al., 1999; Patel et al., 2002). Cp may act as an anti-
inﬂammatory agent by reducing the number of neutrophils attaching to the endothelium and 
by acting as an extracellular scavenger of peroxide (Broadley & Hoover, 1989; Segelmark et al., 
1997). 
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Collectin family includes lung surfactant proteins, conglutinin (a mammalian lectin) and 
mannan-binding lectin (MBL). MBL has been reported in chickens as a minor acute phase 
reactant and an opsonin of the innate immune defence against various microorganisms 
(Nielsen et al., 1999). The family as a whole is considered to mediate the alternative pathway 
of complement, a primitive immune mechanism related to the innate immune system, in an 
antibody-independent manner, thereby contributing to the capacity of the pathway to 
distinguish between self and non-self (Tabel, 1996). 
Fibrinogen (Fb) is involved in homeostasis after tissues injuries by providing a substrate for 
fibrin formation, and in tissue repair and a matrix for the migration of inflammatory related 
cells. Fb specifically binds to CD11/CD18 integrins on the cell surface of migrated phagocytes, 
thereby triggering a cascade of intracellular signals that lead to enhancement of degranulation, 
phagocytosis, antibody-dependent cellular cytotoxicity and delay of apoptosis (Sitrin et al., 
1998; Rubel et al., 2001). 
 
1.3  APPs in veterinary medicine 
Acute phase proteins may provide an alternative means of monitoring animal health. An 
increased focus on the application of APP for this purpose has recently been developed 
(Skinner et al., 1991). Due to a relatively short half life in serum and high response in diseased 
animals (Mackiewicz, 1997), APP serum responses constitute a valid measure of a systemic 
response to an initiating stimulus at the time of blood sampling. Like rectal temperature, APP 
levels are not suitable for establishing a specific diagnosis but can provide objective 
information about the extent of ongoing lesions in individual animals. At the herd level, APP 
might be useful for determining where the spread of the disease is taking place (age group, 
part of the production system), by providing information about the prevalence of ongoing 
clinical and subclinical infections indicated by the high serum concentration of selected APP 
(Petersen et al., 2002) and by serving as a prognostic tool, with the magnitude and duration of 
the acute phase response reflecting the severity of infection (Hirvonen et al., 1999; Hultén et 
al., 2002; Peltola, 1982; Skinner et al., 1991). Distinct positive APPs from some species do not 
behave in the same way in other species; for example Serum Amyloid P-component (SAP) is an 
APP in the mouse, but not in man, and CRP reacts as APP in several monogastric species, but 
not very well in ruminants (Gruys et al., 1994) (Table 1.3). Transferrin, which is a negative APP 
of most mammalian species, reacts as positive APP in chicken (Hallquist & Klasing, 1994; Tohjo 
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et al., 1995). CRP, SAA, Hp and other APPs, have been described as useful for assessing health 
in human patients (Blackburn, 1994; Ferard et al., 2002) and in various animals (Gruys et al., 
1994; Petersen et al., 2004; Toussaint, 2000; Toussaint et al., 1997), including  also marine 
mammalians (Duffy et al., 1996; Funke et al., 1997). 
APP CHICKEN DOG HORSE PIG RUMINANTS 
AGP ▲ ▲ ▲-● ▲ ▲ 
Cp ▲ ▲ ● ● ● 
CRP NC ■ ▲ ▲ ▲ 
Fb ● ▲ ▲-● ▲-● ▲ 
Hp NC ▲ ▲ ▲ ■ 
SAA ▲ ▲ ■ ▲ ▲-■ 
Table 1.3. Classification of APP in domestic animals: ■, major (10–100-fold increase in response to stimuli); ▲, 
moderate (2–10-fold increase); •, minor (<2-fold increase); and NC, not confirmed (Murata et al., 2004). 
 
1.4  Serum Amyloid A (SAA)  
 
The SAA family was originally considered to comprise only a single circulating precursor of the 
amyloid A protein from where its name is derived from. The amyloid A protein is the principal 
component of the secondary amyloid plaques that may be deposited in major organs as an 
occasional consequence of chronic inflammatory disease (Husby et al. 1994). Serum Amyloid A 
(SAA) is associated with the serum high-density lipoprotein (HDL) and is a non-glycosylated 
apolipoprotein with a molecular weight ranging between 11 and 14 KDa, depending on species 
(Benditt & Eriksen, 1977; Nakayama et al., 1993; Gruys et al., 1994). HDL is a sphere of 7-10 nm 
in diameter, and has an apparent molecular weight of 200 KDa (van der Westhuyzen et al., 
1986). The particle consists of a core of esterified cholesterol and triglycerides surrounded by 
apolipoproteins, unesterified cholesterol, and phospholipids (Rosenthal et al., 1976). HDL also 
contains the enzymes lecithin cholesterol acyl transferase (LCAT), which esterifies cholesterol, 
and cholesterol ester transfer protein, which transfers cholesterol esters between lipoproteins 
(Mahley & Innerarity, 1983; Jiao et al.,1980). One major role proposed for HDL is to reverse 
cholesterol transport, which is removing cholesterol from peripheral tissues to the liver for 
catabolism and secretion. This is vital, since the liver is the major site of cholesterol 
degradation and removal. HDL’s role in reverse cholesterol transport is supported indirectly by 
the observation that HDL concentrations are negatively associated with the risk of coronary 
heart disease from atherosclerosis (Lacko, 1994). Under non-inflammatory conditions, HDL 
contains very low levels of SAA (Rosenthal et al., 1976). Once inflammation occurs, SAA levels 
increase dramatically. Most of the SAA is present in the denser HDL3 subclass, and accounts 
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for 20% to 50% of HDL’s total apolipoprotein (van der Westhuyzen et al., 1986); only 5-10% of 
total plasma SAA is associated with the other lipoproteins. The remainder is free or associated 
with albumin (Husby et al., 1994). In tissues it attracts inflammatory cells and inhibits the 
respiratory burst of leukocytes (Linke et al., 1991) and modulates the immune response (Gruys 
et al., 1994). It has been reported to bind lipopolysaccharides (LPS), comparable to LPS binding 
protein (LBP) (Schroedl et al., 2001).    
The SAA family is now known to contain a number of differentially expressed apolipoproteins 
which are synthesized primarily by the liver and can be divided into two main classes based on 
their responsiveness to inflammatory stimuli “Acute phase” SAA (A-SAA) and “Constitutive” 
SAA (C-SAA). The A-SAA, which increases in concentration in the plasma during the acute 
phase response, is mainly synthesized by the hepatocytes, whereas the C-SAA, which is found 
to be associated with HDL under normal conditions and which is not significantly increased 
during the acute phase response, is produced both in the liver and in other organs (Whitehead 
et al., 1992; Steel et al., 1993, 1996; de Beer et al., 1994). In birds, only one SAA type, 
corresponding to mammalian A-SAA, has been described (Guo et al., 1996; Ovelgönne et al., 
2001; Kovacs et al., 2005). There is not only a response difference between A-SAA and C-SAA, 
but various publications also describe different SAA genes that code for A-SAA and its isotypes 
in many species including man.  
 
1.5  SAA structure and expression 
1.5.1 Gene    
 
Multiple SAA genes and proteins have been described for several mammalian species including 
human, mouse, hamster, rabbit, dog, mink, cow, sheep and horse. The high degree of 
conservation of the SAA genes and proteins that has been maintained through the evolution of 
eutherian mammals (Uhlar et al., 1994) extends to other vertebrates including marsupials 
(Uhlar et al., 1996) and fish (Jensen et al., 1997) thereby providing further evidence that they 
are likely to have important biological functions. All of the SAA genes described to date share a 
four-exon three-intron organization which is characteristic of many other apolipoproteins (Fig 
1.6) (Steel & Whitehead, 1994). The SAA genes of human and mouse, which comprise four and 
five members, respectively, are those that have been subjected to the most comprehensive 
analyses. In other mammalian species the SAA family members are less well defined. There are 
at least three transcribed A-SAA genes in dog (Sellar et al., 1991), mink (Marhaug et al., 1990; 
Rygg et al., 1993) and rabbit (Ray & Ray, 1991; Mitchell et al., 1991). In the case of horse, three 
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SAA isoforms have been found in acute-phase serum (Sletten et al., 1989; Hulten et al., 1997). 
There are also at least two A-SAAs in hamster (Webb et al., 1989), and one each in cow 
(Rossevant et al., 1992; Yamamoto eet al., 1998), sheep (Syversen et al., 1994) and wallaby 
(Uhlar et al., 1996). A-SAA isoforms have also been detected in fox, goat sera (Foyn Brunn et 
al., 1995) and in arctic char (a salmonid closely related to trout) (Jensen et al., 1997). 
 
Figure 1.6. Human and Mouse SAA gene structure. Each block represents an exon (Ensembl). 
 
The SAA genes of both the human and mouse lineages have remained in close physical linkage 
(Fig. 1.7) and it seems likely that the SAA genes will be similarly clustered in the genomes of 
other species (Uhlar et al., 1996). The human SAA1, 2, 3 and 4 genes are within 150 kb of each 
other on chromosome 11p15.1 (Sellar et al., 1994a; 1994b). This region of the human genome 
is syntenic with proximal mouse chromosome 7 (Junien & Heyningen, 1990) to which the 
mouse SAA genes were originally mapped (Taylor & Rowe, 1984) and within which the position 
of the cluster, containing Saa1, 2, 3, 4 and 5 and spanning only 45 kb, has been refined (Butler 
et al.,1995; Butler & Whitehead, 1996). The human SAA1 and SAA2 and the mouse Saa1 and 
Saa2 genes all encode A-SAAs. It is impossible to determine the interspecies evolutionary 
relationships of these individual SAA family members based on nucleotide or protein sequence 
comparisons alone (Uhlar et al., 1996). However, their relative map positions and 
transcriptional orientations (Fig. 1.5.2) provide strong evidence that human SAA1 and mouse 
Saa1 (formerly Saa2) are evolutionary homologs, as are human SAA2 and mouse Saa2 [Saa1] 
(Sellar et al., 1994; Butler & Whitehead, 1996). Within each species these two genes have 
almost identical sequences and organizations, suggesting that the A-SAA genes have been 
subjected to recent gene conversion events within each evolutionary lineage (Uhlar et al., 
1996). They are co-ordinately induced during the acute-phase response. 
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Figure 1.7. A comparative map of the human and mouse SAA gene families. The human family spans 150 kb on 
chromosome 11p15.1 while the mouse family spans 45 kb on chromosome 7p; these regions of the human and 
mouse genome are syntenic. Arrows within SAA genes represent 5’3’ orientation of the gene. (Modified from 
Uhlar et al. 1999) 
 
1.5.2 The protein structure 
 
Works based on predictive methods suggested that A-SAA is likely to contain two regions of α-
helix in addition to β-sheet regions (Turnell et al., 1986), the latter being common to all 
amyloid proteins, including amyloid A protein (Glenner, 1980). Several regions of mammalian 
A-SAA proteins that may be important in facilitating the beneficial role(s) SAA may play during 
inflammation, and/or its pathogenic behavior after over-expression during chronic 
inflammation have been identified. It has clearly been established that A-SAA is the serum 
precursor of the amyloid A protein that is found in secondary amyloid deposits by tracking the 
fate of human A-SAA-HDL introduced into mouse in vivo models of amyloidosis (Husebekk et 
al., 1985; Tape et al., 1988).  
A-SAA and C-SAA both associate with HDL, the former being the major HDL-associated 
apolipoprotein during the acute-phase response and the latter being the predominant, 
perhaps only, HDL-associated SAA under normal physiological conditions. The early 
proposition that the lipid-binding, as well as the amyloidogenic, region of A-SAA resides within 
the first 11 N-terminal amino acids (Turnell et al., 1986) is consistent with subsequent findings 
that amyloid A protein which lacks the C-terminal 28 residues, can associate with HDL 
(Husebekk et al., 1987), and that epitopes defined by antibodies raised against N-terminal A-
SAA peptides (residues 1-30) are masked when A-SAA is complexed with HDL (Malle et al., 
1995). The region between residues 29 and 42 in human A-SAA contains two elements, YIGSD 
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and RGN, which are very similar to the distinct cell-binding domains of the two extracellular 
matrix (ECM) cell adhesive glycoproteins, laminin (YIGSR) and fibronectin (RGD), respectively. 
Synthetic peptides of these elements specifically inhibit the receptor-mediated adhesion of 
human T lymphocytes and mouse M-4 melanoma cells to laminin and fibronectin, respectively. 
The above suggests that A-SAA may be able inhibit immune cell migration towards 
inflammatory sites and, perhaps, metastatic processes in vivo (Preciado-Patt et al., 1994). 
The RGD sequence of the ECM adhesive proteins is also the target that facilitates the binding 
of some of the mediators released from activated platelets, e.g. fibrinogen, to the platelet 
integrin glycoprotein IIb-IIIa receptor which is essential in platelet aggregation. It has been 
suggested that the inhibition of platelet aggregation that can be achieved using A-SAA, 
residues 25-76 of A-SAA, or amyloid A protein may occur through the conserved RGN 
sequence (Syversen et al., 1994). Further evidence of A-SAA involvement in platelet 
aggregation is provided by its modulation of the induction of prostaglandin I2α potent 
antiaggregation agent; this is mediated by the first 14 N-terminal amino acids of A-SAA 
(Shainkin-Kestenbaum et al., 1996). A putative calcium-binding sequence, GPGG, between 
residues 48 and 51 (Turnell et al., 1986), is conserved in all SAA sequences identified to date 
except for mouse Saa4, in which the corresponding tetrapeptide is GSGG. Early reports that 
amyloid deposits are rich in calcium and are sites at which Ca2+-dependent protein binding 
interactions occur (Pepys et al., 1979) suggested that this peptide may be important in 
amyloidogenesis. Although relatively few functional studies of the C-terminus of A-SAA have 
been performed, there is evidence that it may facilitate binding to neutrophils. A peptide 
corresponding to residues 77-104, but not peptides spanning other regions, competitively 
inhibits such binding (Preciado-Patt et al., 1996). Interestingly residues 77-104 are usually not 
present in amyloid A deposits, raising the possibility that they are specifically released after 
proteolysis of A-SAA and that they have an immune-related proteolysis of A-SAA and that they 
have an immune-related biological function. Recently A-SAA has also been shown to have 
glycosaminoglycan, i.e. heparin sulfate and heparin, binding activity at its C-terminus between 
residues 77 and 103 (Ancsin & Kisilevsky, 1999) (Fig 1.8). 
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Fig. 1.8. The structure of human A-SAA protein. The 18-amino acid signal peptide is shown (-18 to 0) together with 
the 104 mature protein (1-104). The most frequently observed C-terminus of the amyloid A protein is indicated at 
residue 76. Regions of potential functional importance are indicated by underlining in color, while structurally 
important regions are indicated by shading/hatching. Sites delimiting sequences encoded by exons 2/3 and 3/4 are 
indicated (exon 1 contains only 50 untranslated region). (modified from Uhlar & Whitehead, 1999). 
 
 
1.5.3 Hepatic and extrahepatic production of SAA 
 
The hepatic acute phase response is induced by a wide range of mediators, including IL-1, IL-6, 
TNF-α, leukaemia inhibitory factor (LIF), transforming growth factor β (TGF β), interferon γ (INF 
γ), IL-11, oncostatin, ciliary neurotrophic factor (CNF) and retinoic acid, whereas others such as 
insulin and okadaic acid have inhibitory eﬀects (Steel & Whitehead, 1993; 1994). 
Glucocorticoids have dual actions: they enhance the eﬀects of other mediators on hepatocytes 
(Steel & Whitehead, 1993; 1994) and at the same time downregulate the production of, for 
example, TNF-α and IL-1 by macrophages and polymorphonuclear cells (PMN). The above 
mediators act by binding to their respective receptors on the cell surface. After binding they 
are internalized and/or transmit signals into the cells to eﬀect a number of diﬀerent 
intracellular regulatory mechanisms, activation and de novo synthesis of transcription factors 
and changes in processing and stability of RNA, translation eﬃciency and protein secretion.  
A-SAA mRNA and protein synthesis are induced in vivo during the inflammatory response to 
challenges such as tissue injury, infection and trauma in all vertebrate species. These 
challenges, which can be experimentally produced using agents such as bacterial 
lipopolysaccharide (LPS), casein, turpentine, AgNO3 and surgery, induce the pro-inflammatory 
cytokine cascade. The principal cytokines involved in the induction of A-SAA are IL-1, TNF-α 
and IL-6. Other cytokines that may be involved either directly or indirectly in A-SAA induction 
include IL-2, interferon-γ (IFN-γ) and ciliary neutrophic factor (Numerof et al., 1992; Fantuzzi et 
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al., 1995). In addition to IL-6 and ciliary neutrophic factor, four other IL-6 type cytokines, i.e. IL-
11, leukemia inhibitory factor, oncostatin M and cardiotrophin-1, induce A-SAA when 
administered to mice. Glucocorticoids, which are also released during inflammation, have been 
shown to enhance cytokine-induced A-SAA expression.  
Although the liver is the major site of APP synthesis, the extrahepatic tissue/cellular expression 
of a wide range of APPs has been documented (Colten, 1992). In most mammalian species, 
SAA1 and SAA2 are predominantly synthesized in the liver while SAA3 is the main isoform 
expressed at extrahepatic sites (Husby et al., 1994). 
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SPECIES ORGANS OR CELL TYPES SAA TYPE MRNA PROTEIN REFERENCES 
Human  Brain  
Pituitary gland 
Breast  
Kidney 
Placenta 
Pancreas 
Prostate 
Skin 
Spleen 
Thyroid 
Tonsil 
Esophagus 
Stomach 
Large intestine 
Small intestine 
Synovial tissue 
Cartilage  
Ns  
Ns 
SAA1, SAA2, SAA4 
SAA1, SAA2, SAA4 
Ns 
Ns 
Ns 
Ns 
SAA1, SAA2, SAA4 
Ns 
Ns 
SAA1, SAA2, SAA4 
Ns 
SAA1, SAA2, SAA4 
Ns 
SAA1, SAA2, SAA4 
A-SAA 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Nd 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Nd 
Nd 
+ 
+ 
+ 
+ 
Urieli-Shoval et al. 1998 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kumon et al. 1999; O’Hara et al. 2000 
Vallon et al. 2001 
Rabbit Brain 
Heart 
Lung 
Spleen 
Kidney 
Small and large intestine 
Ovary 
Synovium 
Cartilage 
SAA3 
SAA3 
SAA3 
SAA3 
SAA3 
SAA3 
SAA3 
SAA3 
SAA3 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
++ 
Nd 
Nd 
Nd 
Nd 
Nd 
Nd 
Nd 
+ 
+ 
Rygg et al. 1993 
Marhaug et al. 1997 
 
 
 
 
 
Vallon et al. 2001 
 
Mink  Convoluted tubules of kidney 
Endometrium   
SAA1, SAA2 
SAA1, SAA2 
+ 
+ 
Nd 
Nd 
Marhaug et al. 1997 
 
Chicken  Amyloidotic synovium SAA + Nd  Ovelgonne et al. 2001 
Duck  Lung 
Bursa di Fabrizio 
SAA 
SAA 
+ 
+ 
Nd 
Nd  
Stepanets et al. 2005 
Cow  Colostrum  
Mammary epithelial cells 
M-SAA3 
M-SAA3 
Nd 
+ 
+ 
Nd  
McDonald et al. 2001 
Sheep  Colostrum  M-SAA3    
Horse  Colostrum  M-SAA3    
Pig  Colostrum  M-SAA3    
 
Table 1.4. Extrahepatic sites of SAA production. Ns: no specific type of SAA; Nd: not done. 
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1.6. SAA functions and disease association 
 
The A-SAA protein structure has been highly conserved through evolution and this, together 
with the dramatic induction of A-SAA expression in response to potentially life threatening 
physiological challenges, suggests a critical role in the acute-phase response. The 
concentration of SAA is usually low in normal plasma (1-5 mg/L) and its half life time is short 
(40-60 minutes). The mechanism and the site of its clearance are not known. The best 
documented clinical condition associated with sustained high expression of A-SAA is amyloid A 
amyloidosis. However, the range of clinically important functions that have been proposed for 
the SAA family members include some that may also have other negative consequences during 
chronic inflammation. The increase in SAA concentration during inflammation and its 
persistence despite short survival implies a specific role for SAA during inflammation or chronic 
infection. Indeed, several functions were attributed to SAA. Individually, none is significantly 
dominant, but when integrated, they seem to counteract the side effects of inflammation. 
 
1.6.1. Immune-related functions 
 
There are some reported immune-related functions of A-SAA. It can induce extracellular matrix 
(ECM) degrading enzymes, such as collagenase, stromelysin, matrix metalloproteinases 2 and 
3, which are important for repair processes after tissue damage. It was also reported the 
capability to induce pro-inflammatory cytokines such as IL-1β and TNF-α. In vitro studies 
evidenced that A-SAA can act as a chemoattractant for immune cells as monocytes, 
polimorphonuclear leukocytes, mast cells and T lymphocytes.  
 
1.6.2. Lipid-related functions 
 
When A-SAA is released into the circulation it is incorporated into HDL, the class of lipoprotein 
particles that play an important role in the prevention of atherosclerosis by both mediating 
reverse cholesterol trasport and inhibiting the lipid (LDL) oxidation that promotes foam cells 
formation. There are two main hypotheses on the role that A-SAA plays in modulating 
cholesterol transport during inflammation. It alters reverse cholesterol transport to allow 
delivery of lipid, particularly cholesterol, via HDL to periperal cells that may have an increased 
requirement for cholesterol to facilitate tissue regeneration at inflammatory sites. The other is 
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that A-SAA facilitates removal of the large quantities of cholesterol liberated at sites of tissue 
damage during inflammation. In addition to its association with HDL, a number of lines of 
evidence implicate A-SAA in lipid metabolism/transport. A-SAA binds cholesterol and promotes 
its cellular uptake (Liang & Sipe, 1995; Liang et al., 1996) and A-SAA-HDL particles have a 
higher affinity for macrophages and a lower affinity for hepatocytes than HDL (Kisilevsky & 
Subrahmanyan, 1992). Furthermore, several enzymes involved in cholesterol metabolism, 
including lecithin-cholesterol acyltransferase, group-IIA non-pancreatic secretory phospolipase 
A2 (sPLA2) and neutral cholesterol ester hydrolase, are affected by induction of A-SAA during 
the acute-phase response.  
 
1.6.3. Anti-inflammatory roles 
 
Almost two decades ago, A-SAA was demonstrated to be implicated in the suppression of in 
vitro immune responses to antigens by affecting T cell-macrophage interactions and helper T 
lymphocyte function (Aldo-Benson & Benson, 1982). Human A-SAA was subsequently found to 
be a potent inhibitor of lymphocyte, HeLa and MRC5 cell function (Peristeris et al., 1989). A 
potential feedback relationship between SAA and immunoregulatory cytokines was proposed 
based on the observation that A-SAA inhibits IL-1-induced and TNF-induced fever in mice 
(Shainkin-Kestenbaum et al., 1991). IL-1 and TNF cause fever by inducing prostaglandin E2 
synthesis in the hypothalamus; prostaglandin E2 production correlates directly with the 
magnitude of the fever (Dinarello et al., 1988). Platelet aggregation has also been reported to 
be inhibited by A-SAA, and A-SAA modestly induces prostaglandin I2 which is also an 
antiaggregation agent (Syversen et al., 1990; Shainkin-Kestenbaum et al., 1996). As both 
platelets and the range of mediators released by them upon activation are involved in 
inflammatory and thrombotic processes, these findings suggest that A-SAA may act to down-
regulate such pro-inflammatory events during the acute-phase response. 
A-SAA has also been reported to bind to neutrophils and, like other apolipoproteins such as 
ApoA-I (Blackburn et al., 1991), inhibit the oxidative burst response, suggesting that it may 
help prevent oxidative tissue damage during inflammation (Linke et al., 1991). However, this 
effect may be concentration-dependent; in a recent study, acute phase concentrations of rhA-
SAA could inhibit both directed neutrophil migration and degranulation (Gatt et al., 1998), 
whereas the inhibition of respiratory burst was restricted to lower concentrations. These 
results suggest that A-SAA may produce quite different effects according to local concentration 
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and that the anti-inflammatory effects intrinsic to this APP may be selective and specific rather 
than systemic. 
 
1.6.4. SAA and Amyloidosis 
 
A-SAA is the serum precursor of amyloid A protein which is the principal component of the 
amyloid deposits found in the heterogeneous group of disorders, the amyloid A amyloidoses 
(Husby, 1994). One of these, the reactive amyloidosis, is a well-documented occasional clinical 
consequence of chronic inflammation (e.g. rheumatoid arthritis) and recurrent acute 
inflammatory episodes (e.g. tuberculosis). 
The predominant amyloid A protein type found in amyloidotic tissues corresponds to the N-
terminal two thirds of A-SAA, i.e. the first 76 residues of mature human A-SAA (Husebekk et 
al., 1985). However, both smaller and larger amyloid A protein types, 45-95 residues, have also 
been found (Husby et al., 1994; Liepnieks et al., 1995; Westermark et al., 1990; Parmelee et al., 
1982). Multiple proteolytic cleavage events may be involved in the processing of A-SAA as it 
appears to be degraded first into an intermediate product with the same size and antigenic 
properties as amyloid A protein and is subsequently processed further. Amyloid A amyloidosis 
may therefore be the result of the incomplete digestion, and consequent accumulation, of 
amyloidogenic intermediate peptides of A-SAA. 
A large number of cell-associated and serum proteases have been implicated in the 
degradation of A-SAA (Table 1.5).  
 
PROTEASES 
Cell-associated activities 
Serum serine proteases (thrombin, kallikrein and plasmin) 
Elastase, collagenase and stromelysin 
Cathepsin B 
Aspartate proteases and Cathepsin D 
Cathepsin G 
Table 1.5. proteases involved in the degradation of A-SAA 
 
A-SAA is probably degraded after its disassociation from HDL, as full-length A-SAA can be 
found in amyloid fibrils (Westermark et al., 1982; Arai et al., 1994). Furthermore, lipid-free A-
SAA can be degraded in vitro to form fibrils (Yamada et al., 1994). In addition, A-SAA 
degradation in vivo is inhibited by lipoproteins, in particular HDL, and differences between the 
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plasma clearance rates of A-SAA and ApoA-I also suggest that the former is not associated with 
HDL when it is degraded (Bausserman & Hebert, 1984). 
Mouse A-SAA can bind to two of the major components of the basement membrane, i.e. 
laminin and type-IV collagen, with high and low affinity, respectively. Its binding to laminin is 
inhibited by entactin, a protein that normally binds laminin. As the basement membrane 
matrix appears to be disrupted in the vicinity of amyloid deposits, these interactions further 
support the involvement of A-SAA as an active, rather than a passive, participant in the process 
of amyloidosis (Ancsin & Kisilevsky, 1997). Inflammatory macrophages and reticuloendothelial 
cells have both been implicated in the formation of amyloid A protein and amyloid fibrils from 
A-SAA: both processes can occur intracellularly (Takahashi et al., 1989). Mouse peritoneal 
macrophages can bind either HDL or A-SAA-HDL, which undergo receptor-mediated 
endocytosis and subsequent retro-endocytosis (Rocken & Kisilevsky, 1997). The binding of the 
latter probably involves heparin sulfate for which A-SAA has a binding site. Mouse peritoneal 
macrophages can also endocytose exogenous mouse Saa1 and Saa2, which are transported to 
endosome-lysosomes and are partially degraded to products similar in mass to amyloid A. 
Although derivatives of SAA1 and SAA2 proteins are both found in human and mouse amyloid 
A deposits, those from SAA1 predominate (Bell et al., 1996; Meek et al., 1986). This bias in 
favor of SAA1 deposition is supported by in vitro studies in which rhSAA1 had greater amyloid 
fibril-forming potential than either rhSAA2 or rhSAA4 (Yamada et al., 1994). 
 
Fig. 1.9. Synthesis of SAA and catabolic pathway leading to amyloidogenesis (Yamada et al.,1999). 
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1.7. Bovine SAA 
 
Measurements of serum concentration have demonstrated that SAA is a major acute phase 
protein in cattle, but its diagnostic value as an indicator of inflammation in clinical 
investigation has not been determined.  
In cattle, an increased SAA serum and plasma concentration has been found following 
experimentally induced and naturally occurring inflammation as well as experimental and 
natural infection. SAA has been shown to reflect the severity of mastitis; cows with clinical 
mastitis had almost 100-fold levels of SAA in serum and milk compared with healthy cows 
(Eckersall et al., 2001). 
A total of seven different SAA isoforms were characterized in the serum of cows with chronic 
inflammation or amyloidosis and in healthy cows. The isoforms are distinguishable using the 
isoelectric point (pI) in 2-dimensional electrophoresis. Isoforms of pI 5.2 and 8.6 are the only 
two identified in amyloidotic sample (Takahashi et al., 2009). SAA1 and SAA2 are expressed 
constitutively by liver and SAA3 is expressed locally and also present in milk. This last isoform is 
also called Milk Amylod A (MAA) because it was found in milk from dairy cows (Eckersall et al., 
2001; McDonald et al., 2001).  
The sequence data obtained from genomic walking revealed a four-exon, three-intron 
organization for bovine MAA, typical of the other sequenced SAA genes (Ulhar & Whitehead, 
1999). Exon 1 contained a 53bp 5’-untraslated region (UTR), downstream and adjacent to this 
first exon was a 556bp intron. The second exon (92bp) contains the beginning of the coding 
sequence for the MAA gene precursor protein and  exon 3 (139bp) encoded the next 46 
aminoacids. Exon 4 encoded the last 55 aminoacids (Fig. 1.10). The splice junction for all the 
three introns conformed to the highly conserved 5’-GT/AG-3’ consensus sequence for splice 
donor/acceptor sites at the two ends of an intron. A polyadenilation signal (AATAAA) was 
located 97 nt downstream to the STOP codon and was 26 nt upstream of a GT-rich region, 
typically found 11 to 30 nt after this site (Larson et al., 2006).  
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1.8. Aims of the thesis 
 
The aim of the thesis is to go insight the expression and some functions of SAA.  
From a clinical perspective the availably of a quick, and reliable, diagnosis marker specific for 
inflammatory diseases of cattle is of great importance. Acute phase proteins are good 
candidates. Unfortunately, few information are available about their functions, as well as their 
localization or local expression. This information are very important given the very different 
behavior of acute phase proteins among different species. 
Therefore, the first part of the thesis analyze the possible relationship of Water Buffalo SAA 
with an important defensive function during natural occurring bacterial intramammary 
infection, was assessed, with the aims to evaluate if high concentrations of SAA, similar to 
those found during systemic reaction, may influence the resolution of inflammatory response. 
The second part of the thesis was devoted to analyze the possible local, extra-hepatic, 
expression of Bovine SAA, in order to assess the origin of the protein and the possibility of a 
local concentration in milk and dairy product as fibrils. This concentration should lead the 
possibility of transmission of fibrils between species and induced the amyloidotic 
degeneration. 
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Chapter 2 
 
Acute Phase Response in Water Buffaloes 
 
2.1   INTRODUCTION 
 
2.1.1 Water buffalo in Italy 
 
In Europe, Italy is the main producer of buffalo milk. Reasons for increasing interest in buffalo 
breeding during recent years are the popularity of buffalo Mozzarella cheese, and the absence 
of quotas in the European Community for this production. In addition, buffalo milk is more 
valuable; farmers typically receive at least twice the price relative to bovine milk. Italian water 
buffalo (Bubalus bubalis), typically reared in central middle and southern Italy, also have been 
recently introduced in northern Italy. Italian buffaloes produce small quantities of milk; the 
average production in a standardized lactation length (270 days) is about 2100 kg 
(Associazione Italiana Allevatori, 1999; Catillo et al., 2002). 
Milk from buffaloes differs from that from cattle. The biggest difference is with respect to fat. 
In cattle, the milk contains between 3 to 5 %, depending on feed and breed. In buffalo milk the 
average fat content is usually 7 to 8% but may be as high as 13% in some breeds. Buffalo milk 
fat has a higher melting point than that of cattle, due to its higher proportion of saturated fatty 
acids. Phospholipids and cholesterol are lower in buffalo milk. It is also more resistant against 
oxidative changes. The content of protein, lactose and ash is somewhat higher in buffalo milk 
than in cattle milk. Buffalo milk lacks or only contains traces of β-carotene, this makes the milk 
look very white, as opposed to cattle milk which has a slight yellow shade. In buffalo milk, 
vitamin A is present instead of its precursor. The different types of casein found in bovine milk 
are found in buffalo milk, although in slightly different proportions. (Table 2.1). 
 
MILK COMPOSITION BOVINE BUFFALO 
Kcal/kg 740 1258 
Proteins (g/kg) 31 45 
Lipids (g/kg) 40 87 
Lactose (g/kg) 48 48 
Ca (g/kg) 1.2 2.0 
P (g/kg) 0.9 1.2 
Table 2.1. Composition of bovine and buffalo milk. 
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2.1.2 What is mastitis?   
 
Mastitis (mast = udder; itis = inﬂammation) results from the inﬂammation of the mammary 
gland, due to a wide spectrum of bacterial strains, algae and fungi (Pyorala, 2003). The severity 
of the inﬂammation can be classiﬁed into sub-clinical, clinical and chronic forms, and its degree 
is dependent on the nature of the causative pathogen and on the age, breed, immunological 
status and stage of lactation of the animal. 
Sub-clinical mastitis is difficult to detect due to the absence of any visible indications, and it 
has major cost implications. Chronic mastitis is an evolutive form of clinical or sub-clinical 
mastitis and results in persistent inﬂammation of the mammary gland.   
Normally, the teat canal is tightly closed by sphincter muscles, preventing the entry of 
pathogens. It is lined with keratin, a waxy material derived from stratiﬁed squamous 
epithelium that obstructs the migration of bacteria and contains antimicrobial agents, such as 
long-chain fatty acids, that assist in combating the infection. However, the efficiency of keratin 
is restricted (Capuco et al., 1992; Paulrud, 2005). Fluid accumulates within the mammary gland 
as parturition approaches, resulting in increased intramammary pressure and mammary gland 
vulnerability caused by the dilation of the teat canal and leakage of mammary secretions 
(Sordillo & Streicher, 2002). Additionally, during milking, the keratin is ﬂushed out and there is 
distension of the teat canal (Rainard & Riollet, 2006). The sphincter requires about 2 hours 
returning back to the contracted position (Capuco et al., 1992). Once inside the teat, bacteria 
must also elude the cellular and humoral defence mechanisms of the udder (Sordillo & 
Streicher, 2002). If they are not eliminated, they start multiplying in the mammary gland (Fig. 
2.1). They liberate toxins and induce leukocytes and epithelial cells to release 
chemoattractants, including cytokines such as tumour necrosis factor-α (TNFα), interleukin 
(IL)-8, IL-1, eicosanoids (like prostaglandin F2α [PGF2α]), oxygen radicals and acute phase 
proteins (APPs) (e.g. α1-acid glycoprotein [AGP], haptoglobin [Hp], serum amyloid A [SAA]). 
This attracts circulating immune effector cells, mainly polymorphonuclear neutrophils (PMNs), 
to the site of infection (Paape et al., 2003; Zhao & Lacasse, 2008). PMNs act by engulﬁng and 
destroying the invading bacteria via oxygen-dependent and oxygen-independent systems. 
They contain intracellular granules that store bactericidal peptides, proteins, enzymes (such as 
myeloperoxidase) and neutral and acidic proteases (such as elastase, cathepsin G, cathepsin B 
and cathepsin D). The released oxidants and proteases destroy the bacteria and some of the 
epithelial cells, resulting in decreased milk production and release of enzymes, such as N-
acetyl-β-D-glucosaminidase (NAGase) and lactate dehydrogenase (LDH) (Fig. 2.1). Destruction 
of most of the PMNs takes place by apoptosis once their task is fulﬁlled. Subsequently, 
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macrophages engulf and ingest the remaining PMNs (Paape et al., 2002; Paape et al., 2003). 
The dead and sloughed off mammary epithelial cells, in addition to the dead leukocytes, are 
secreted into the milk, resulting in high milk SCCs. If the infection persists, internal swelling 
within the mammary epithelium, not normally detectable by an external examination, can 
occur. The mammary gland alveoli become damaged and start losing anatomical integrity (Fig. 
2.1). The blood–milk barrier is breached, causing extracellular ﬂuid components, such as 
chloride, sodium, hydrogen, potassium and hydroxide ions, to enter the gland and mix with the 
milk (Zhao & Lacasse, 2008). When extensive damage to the blood–milk barrier has occurred, 
blood might be detected in the milk. This leads to visible changes on the udder, such as 
enhanced external swelling and reddening of the gland. Changes also occur in the milk, 
including increased conductivity, increased pH, raised water content and the presence of 
visible clots and ﬂakes (Kitchen, 1981; Milner et al., 1996; Zhao & Lacasse, 2008). This marks 
the initial stage of clinical symptoms, and the most severe infections might ultimately result in 
the death of the animal.  
  
 
Figure 2.1. Schematic representation of mastitis development in an infected udder. Environmental and contagious 
microorganisms invade the udder through the teat cistern. They then multiply in the udder where they are attacked 
by neutrophils. The epithelial cells lining the alveoli release enzymes like NAGase and LDH and also secrete anti-
microbial compounds (modified from Viguier et al., 2009).  
 
2.1.3 Bovine and Water buffalo mastitis   
 
Bovine mastitis is a disease with high incidence worldwide, even in herds with mastitis control 
programs. It causes considerable economic losses due to decreases in the quality and quantity 
of milk production, increases in the cost of treatment and veterinary services, and animal 
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waste. Mastitis is inﬂammation of the mammary gland that develops as a response to 
pathogenic microorganisms entering through the teat canal and multiplying inside the gland 
(Bannermann et al., 2004). The risk of acquiring the disease may be increased by chemical, 
physical, or traumatic factors. For this reason, mastitis can be considered as a multifactor 
disease that includes: 1) the bovine as host; 2) the microorganisms as causal agents; and 3) the 
environment, which affects both the cow and the causal microorganism. In a dairy herd, it is 
possible to ﬁnd healthy cows, cows with one affected quarter, and cows with four quarters 
affected (Barkema et al., 1997).  
This variability suggests that the incidence and prevalence of mastitis depends on differences 
in the mammary gland susceptibility to intramammary infection (IMI). Among factors that 
inﬂuence bovine IMI susceptibility are parity, nutrition, stage of lactation, milk production, and 
breed (Smith et al., 1997; Barkema et al., 1999). For example, cows with the highest productive 
capacity during partum and early lactation are the most sensitive to infection by 
environmental pathogens (Wagter et al., 2000; Burvenich et al., 2003). It is possible that during 
the peripartum period, cows experience certain alterations in defence mechanisms associated 
with either changes in hormonal proﬁle or metabolic and physiologic stresses (Mallard et al., 
1998) (Fig. 2.2). 
 
Figure 2.2. Frequency of intramammary infections during the lactation cycle. 
 
There are many different contagious and environmental bacteria that cause mastitis (Table 
2.2). Contagious bacteria live and multiply in infected mammary gland and can be spread from 
cow to cow or among quarters in the same animal. This group of bacteria includes 
Staphylococcus aureus, Streptococcus agalatiae, and several Mycoplasma and 
Arcanobacterium spp. (Dego et al., 2002; Zadoks et al., 2001; Bradley, 2002). Environmental 
pathogenic bacteria are present in the animal’s environment and their presence in mammary 
 - 36 - 
 
gland mainly occurs by teat contamination. This group includes Escherichia coli, Streptococcus 
dysgalactiae, Streptococcus uberis, Klebsiella pneumoniae, and Bacillus spp. 
 
Staphylococcus aureus Mycoplasma bovis 
Streptococcus agalactiae Mycoplasma californicum 
Streptococcus dysgalactiae Mycoplasma canadense 
Streptococcus uberis Klebsiella pneumonie 
Corynebacterium pyogenes Enterobacter spp 
Bacillus cereus  
Escherichia coli Prototheca 
Proteus spp Fungi  
Pseudomonas aeruginosa  
Table 2.2. Micro-organisms frequently isolated from clinical bovine mastitis. 
 
As said above, mastitis is one of the most costly diseases in dairy production, and even though 
the buffalo has been traditionally considered less susceptible to mastitis than cattle, some 
researchers have shown similar mastitis frequencies for the two species (Kalra & Dhanda, 
1964; Badran, 1985; Bansal et al., 1995; Moroni et al., 2006). Buffaloes have some 
characteristics that may contribute to greater risk of mastitis. For example, the udder is more 
pendulous and teats are longer in comparison with cattle. Conversely, the buffaloes have a 
long narrow teat canal, which may be expected to prevent the invasion of microorganisms. The 
type of bacteria most frequently isolated in milk samples of buffaloes, with mastitis in previous 
studies, has been coagulase-negative staphylococci (CNS) followed by Corynebacterium spp. 
and Streptococcus spp. (Chander & Baxi, 1975; Paranjabe & Das, 1986; Saini et al., 1994; 
Naiknaware et al., 1998; Moroni et  al., 2006). Staphylococcus aureus was the most important 
micro-organism responsible for mastitis in buffaloes in one study (Jaffery & Rizvi, 1975).  
 
 
2.1.4 Mammary gland immunology   
 
In general, the immune system is characterized by its capacity to recognize and discriminate 
between foreign invading agents and molecules produced by the organism (Janeway & 
Medzhitov, 2002). The mammary gland performs a variety of immunological functions 
conferring protection; during pre-partum, antibodies secreted in colostrum are produced to 
protect the newborn against infectious agents (Sordillo et al., 1997). 
The mammary gland tissue is protected by two forms of immune defence mechanisms: innate 
immunity and acquired immunity. The innate and acquired immune systems interact closely in 
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an attempt to provide protection against mastitis micro-organisms (Burvenich et al. 2003; 
Sordillo et al., 1997; Rivas et al., 2002). 
First, the innate immune response stimulates the acquired immune response and inﬂuences its 
nature. Second, the acquired immune response uses many innate immune effector 
mechanisms to eliminate micro-organisms, and its action frequently increases innate immune 
response antimicrobial activity. The efficiency of these responses determines mammary gland 
susceptibility or resistance to infection. 
Innate immunity predominates in the early stage of infection and is mediated by macrophages, 
neutrophils, natural killer cells (NK) and cytokines. It recognizes and responds to different 
pathogens, even if they are invading the mammary gland for the ﬁrst time. In particular, 
bacteria have different cell wall structures that are recognized by speciﬁc plasma membrane 
receptors. These structures are lipopolysaccharide (LPS), peptidoglycan (PGN), and lipoteichoic 
acid (LTA), which constitute the pathogen-associated molecular patterns (PAMPs) (Han et al., 
2003; Bannerman et al., 2004). These PAMPs are recognized by Toll-like receptors (TLRs), 
which induces production of cytokines and other endogenous mediators that are essential in 
protection against pathogenic microorganisms (Lembo et al., 2003).  
The teat canal is the ﬁrst line of defence, because bacteria must penetrate through it to cause 
an IMI. The function of the teat sphincter muscle is to keep the oriﬁce closed and thereby 
isolate the interior of the mammary gland. This means that any damage of this structure is 
related to an increase in the incidence of mastitis (Myllys & Honkanen-Buzalski, 1994). The teat 
canal is lined with keratin, which provides an additional physical barrier, preventing bacterial 
migration towards the cistern (Sordillo & Streicher, 2002; Capuco et al., 1994).  
The second line of defence consists of neutrophils, macrophages, and lymphocytes. These cells 
regulate both innate and acquired immune responses (Sordillo et al., 1997; Sordillo et al., 
2002; Soltys & Quinn, 1999). In mammary gland defence against bacterial infection, tissue or 
milk macrophages recognize the invading pathogen and initiate the inﬂammatory response. In 
this response, pro-inﬂammatory cytokines induce neutrophil recruitment to the mammary 
gland (Zhang & Issekutz, 2002; Rainard, 2003). When macrophages recognize bacteria, they 
release pro-inﬂammatory cytokines such as TNF-α, IL-1β and IL-6, stimulating the bactericidal 
activity of neutrophils and also producing prostaglandins and leukotrienes, which increase the 
local inﬂammatory reaction (Bannerman et al., 2004; Boulanger et al., 2003; Stein et al., 2003). 
IL-6 produced by macrophages is involved in acute septic shock during mastitis caused by 
coliforms or S. aureus. This cytokine facilitates the exchange of neutrophils for monocytes in 
the mammary gland, which is necessary for reduction of the deleterious effects of neutrophils. 
Also, IL-6 is one of the main regulatory cytokines of acute phase protein synthesis in 
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hepatocytes (Slebodzinski et al., 2002; Ohtsuka et al., 2001), and also a local production in the 
mammary gland (Eckersall et al., 2001). 
 
2.1.5 Current approaches for diagnoses of mastitis  
 
Early diagnosis is of the utmost importance due to the high costs of mastitis. European Union 
legislation (Regulation 853/2004) stresses that milk selected for human consumption must 
originate from healthy animals. Diagnostic methods have been developed to check the quality 
of the milk through detection of mammary gland inﬂammation and diagnosis of the infection 
and its causative pathogens. Currently, assays usually include measurement of SCCs, enzymatic 
analysis and the California milk clotting tests (Pyorala, 2003). In Europe, elevated SCCs above 
200.000 cells/mL are widely used as an indicator of mastitis (Schukken et al., 2003) and are 
determined using haemocytometers or cell counters. Colorimetric and ﬂuorometric assays 
have been developed for measuring the concentrations of enzymes elevated in milk during 
mastitis (e.g. NAGase or LDH). Use of culturing techniques for the detection of mastitis-causing 
micro-organisms is still the gold standard, although it is very labour-intensive and therefore 
expensive. 
Mastitis can also be detected using “cow-side” or “on-site” tests, which can be used by both 
farmers and veterinarians and which require relatively little training. One of the oldest and 
best known is the California mastitis test (CMT) (Schalm & Noorlander, 1957). It is based on the 
principle that the addition of a detergent to a milk sample with a high cell count will lyse the 
cells, release nucleic acids and other constituents and lead to the formation of a “gel-like” 
matrix consistency. However, the interpretation can be subjective, and this might result in 
false positives and negatives. Mastitis can also be detected via changes in conductivity or pH. 
Although these effects are easy to monitor, they are relatively insensitive. Thus, there is a 
major need for new biomarkers that are speciﬁc for mastitis, easy to detect and occur at a very 
early stage. 
Technological advances, together with increased proteomic and genomic information, have 
resulted in improvements in the sensitivity of assays used for the detection of mastitis. 
Immunoassays, such as enzyme-linked immunosorbent assay (ELISA), can provide a reliable 
and inexpensive approach provided that suitable antibodies are available against speciﬁc 
inﬂammation-related biomarkers or the causative microorganisms. Numerous immunoassays 
have been developed for the detection of pathogens in milk (Barbuddhe et al., 2002; Arimi et 
al., 2005; Arora et al., 2006) and are used for monitoring milk quality. However, very few 
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studies have been undertaken for the development of immunoassays that detect pathogens in 
milk as deﬁnitive causative agents of mastitis. Such assays might also be useful for mastitis 
detection. However, studies to validate this assumption are required. Immunoassays can also 
be used to detect inﬂammation-related biomarkers present in the milk at different stages of 
sub-clinical mastitis. For example, single radial immunodiffusion was developed for the 
quantitative measurement of bovine α1-acid glycoprotein (AGP) in serum. The mean serum 
value of AGP in healthy cattle was 283.2 µg/ml. Elevated values were observed in cattle with 
traumatic pericarditis, arthritis, mastitis, pneumonia and mesenteric liponecrosis (Tamura et 
al., 1989). AGP in cattle with experimentally induced abscesses, increased in concentration for 
7 to 10 days after F.necrophorum inoculation and high concentration was also found in 
naturally affected cattle (Motoi et al., 1992). A second acute phase protein suggested as a 
potential marker for diagnosis is Haptoglobin (Hp). Its concentrations have been reported to 
increase signiﬁcantly in plasma, as well as in milk, during mastitis and (Gronlund et al., 2003). 
Hiss and co-workers (2004) developed an ELISA for its detection, with a detection limit of 0.07 
µg/mL in both milk and serum. Serum amyloid A (SAA) is another example of an APP marker 
that shows elevated levels in mastitic milk (Eckersall, 2007; Akerstedt et al., 2007; Molenaar et 
al., 2009). Szczubial and colleagues (2008) were able to detect elevated concentrations of SAA 
of up to 322.26 µg/mL in mastitic milk (compared with normal levels of 11.67 µg/mL) using a 
commercially available solid-phase-sandwich ELISA (Tridelta PhaseTM range SAA kit, Tridelta 
Development Ltd, Ireland).  
There have also been signiﬁcant developments in nucleic-acid-based testing for the 
identiﬁcation of the pathogens. The genome sequences of many of the major mastitis-causing 
pathogens are now available and can be utilized to develop nucleic acid-based testing 
methods, such as PCR. Such tests are generally more expensive than, for example, 
immunoassays. However, they are highly sensitive and speciﬁc, can be performed rapidly and 
can overcome the sensitivity and time-constraints sometimes encountered with culture-based 
tests (Studer et al., 2008) and thus could complement or replace them in the long-term. PCRs 
allow the identiﬁcation of closely related organisms within a few hours. Multiplex PCR and 
real-time PCR assays that can simultaneously detect different mastitis-causing organisms in 
milk samples have been described (Cremonesi et al., 2005; Gillespie et al., 2005; Cai et al., 
2005), and the most recently developed assay is capable of detecting 11 of the major mastitis-
associated pathogens, including Escherichia coli, Staphylococcus aureus, Streptococcus 
agalactiae and Streptococcus uberis (Koskinenen et al., 2009).  
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2.1.6 Acute Phase Proteins and mastitis 
 
In bovine, SAA was identified as potential marker of mastitis (Hirvonen et al., 1999; Pedersen 
et al., 2003), even if there are no evidence of a correlation between SAA levels and severity of 
the pathology (Eckersall et al., 2001). In bovine with experimentally induced mastitis, milk 
concentration of SAA increases before the increase of somatic cells (Pedersen et al., 2003). 
SAA levels in milk from an infected udder can increase to 110 µg/ml (Eckersall et al., 2001; 
2006; Gronlund et al., 2003; Nielsen et al., 2004). The changing in concentration can be used as 
an early marker of mastitis.  
During mastitis the protein are produced by liver and it can reach the site of inflammation by 
blood. It is known that exist a local production of acute phase protein, and in particular the 
milk SAA (MAA) is produced by the mammary gland (Eckersall et al., 2001; 2006; Larson et al., 
2005; McDonald et al., 2001; Molenaar et al., 2009; Weber et al., 2006). The production of SAA 
mRNA by cells in extrahepatic tissues is an interesting feature, in that these cells can provide a 
local source of SAA proteins. The locally expressed proteins may be produced under conditions 
that do not evoke the systemic acute-phase response and may play a role related to the site of 
expression. The properties and the physiological significance of the SAA family of proteins in 
normal and in disease states are poorly understood. In addition to SAA release to the 
circulation by the liver during an acute-phase response, one or more SAA proteins produced in 
tissues may be constitutively expressed to serve as a first line of defence or in proper 
maintenance of tissues (Urieli-Shoval et al., 1998). 
 
In water buffalo there are no evidence of a possible correlation between somatic cell counts 
(SCC), the most common diagnostic tool for diagnosis of mastitis, and the presence of SAA. For 
this reason it should be useful to identify complementary or alternative tools for diagnoses and 
between them the measurement of acute phase proteins.   
All these information fail in buffalo specie. The acute phase proteins sequences are unknown, 
and also their concentration in physiological and pathological conditions are not established.  
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2.2    MATERIALS AND METHODS 
 
2.2.1 Samples 
 
Samples were collected from healthy water buffaloes and buffaloes with intramammary 
infections (IMI). 
Blood specimens were collected by venipuncture into serum collection tubes. Samples were 
kept for up to 4 hours at room temperature and centrifuged at 2500g for 15 minutes to 
remove serum from the clot. Serum was stored frozen at –20°C until use.  
Milk samples were collected monthly before each milking and during all lactating period. A 
stream of milk was discarded prior to disinfection of the teat surface using pledges of cotton 
soaked in chlorhexidine.  A sample of 10ml was collected in a sterile container. Whey was 
stored frozen at –20°C until use. 
 
2.2.2 Bacteriological procedures 
 
Bacteriological culturing of milk samples was performed according to standards of the National 
Mastitis Council (NMC, 1999). Ten μl of each milk sample was spread on blood agar plates (5% 
deﬁbrinated sheep blood). Plates were incubated aerobically at 37°C and examined after 24 
hours. Colonies were provisionally identiﬁed on the basis of Gram stain, morphology, and 
hemolysis patterns, and the numbers of each colony type were recorded. Representative 
colonies were then subcultured on blood agar plates and incubated aerobically at 37°C for 24 
hours to obtain pure cultures. Catalase and coagulase production was tested for Gram-positive 
cocci. Speciﬁc identiﬁcation of staphylococci and streptococci were made using commercial 
micromethods (API Staph and API 20 Strep, BioMérieux, Italy). Gram-negative isolates were 
identiﬁed by using colony morphology, gram-staining characteristics, oxidase, and biochemical 
reactions on MacConkey’s agar and API 20E (BioMérieux). Contagious pathogens 
Staphilococcus aureus and Streptococcus agalactiae were considered to cause IMI if at least 
one colony (≥100cfu/ml) was isolated. For other microrganisms, IMI was deﬁned by the 
isolation of ≥500cfu/ml and 1 to 3 colony types. Milk samples from which >3 colony types or 
<500cfu/ml colonies of any micro-organism were isolated were regarded as contaminated or 
uninfected, respectively. No contaminated samples, however, were found. 
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2.2.3 Determination of Somatic cells counts (SCC) 
 
For each milk sample, the SCC was determined by an automated ﬂuorescent microscopic 
somatic cell counter (Bentley Somacount 150, Bentley Instrument, Italy). The instrument 
utilizes a laser based flow cytometry. The laser based counting section uses the fluorescence 
characteristics of the dye to count the cells one by one. Ethidium bromide dye was used for 
speciﬁc binding to DNA in cell nuclei. When cells are exposed to light of a specific wavelength, 
they emit red-orange fluorescent light. The light of cell is detected and counted by a laser scan.  
 
2.2.4 Testing the cross-reactivity of the commercially available assays in water 
buffalo 
 
Serum SAA and AGP concentrations were determined by using immunoenzymatic assays. The 
cross-reactivity of the antibodies included in the commercially available tests with buffalo 
proteins had never been tested before in this species. Therefore, a preliminary step to validate 
the possible utilization of the commercially available assays with buffalo serum was carried 
out. These experiments were performed by testing 1 µl of buffalo serum with SDS-PAGE on a 
12% (for AGP detection) and 15% (for SAA detection) polyacrylamide gel, and Western blotting 
onto nitrocellulose. The membranes were then incubated with different concentrations of 
anti-boAGP and anti-SAA primary antibodies (1:100, 1:200, 1:500, 1:1000, 1:2000, 1:5000, 
1:10000, 1:20000 and 1:40000) using a multiscreen apparatus (Bio-Rad, Italy) and incubated 
for 1, 2 or 3 hours at room temperature. Both antibodies were those included in the 
commercial kits, and were made available by the courtesy of Dr Martin Gallagher, from 
Tridelta Company. Serum AGP positive bands were visualized by immunostaining using an anti-
bovine AGP polyclonal antibody which was, after preliminary experiments, eventually utilized 
at a concentration of 1:40000 for 45 minutes of incubation at room temperature. Detection 
was carried out by enhanced chemiluminescence (ECL) using ImmobilonTM Western 
Chemiluminescence HRP Substrate (Millipore, Italy). Bovine puriﬁed AGP (Ceciliani et al., 2007) 
was used as positive control (50 ng each lane). Serum SAA positive bands were visualized by 
immunostaining using anti-SAA biotinylated monoclonal antibody (1:200 dilution from the 
original antibody included in the kit, incubated overnight at 4°C in order to reduce the 
background), followed by a streptavidin–biotin peroxidase-conjugated complex, using the 
Vectastain ABC kit (Vector Laboratories, UK) and developed using ECL as previously described. 
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2.2.5 Quantification of SAA in serum and milk 
 
Serum Amyloid A was quantified using a commercial solid phase sandwich Enzyme Linked 
Immuno Sorbent Assay (ELISA) kit (Phase Range Serum Amyloid A Assay Tridelta Dev. Ltd, 
Ireland) used for quantification of serum SAA. Each sample was diluted in Dilution Buffer 1X 
(1:500) in a final volume of 50µl and was added to 50µl of a SAA specific biotinilated 
monoclonal antibody (1:100) for 1 hour at 37°C. Each sample was plated in duplicate. The plate 
was then washed three times with Washing Buffer, and then incubated with 100µl of 
Streptavidin-Peroxidase (HRP) (1:4000) for 30 minutes, at room temperature in the dark. The 
plate was washed three times and then incubated with 100µl of 3,3',5,5' tetramethyl-
Benzidine (TMB) for 30 minutes at room temperature. Finally the reaction was stopped adding 
50µl of Stop solution and the absorbance was read in a spectrophotometer at 450nm.  
The mean absorbance for each sample, standard was calculated. The absorbance of the 
standards was plot against the standard concentration and the best smooth curve through 
these points was drawn to construct the standard curve. The concentrations of the test 
samples and controls were calculated from the standard curve by multiplying the interpolated 
value by the appropriate dilution factor. 
The same protocol was used for SAA quantification in milk. Raw milk was centrifuged at 4000g 
for 20 minutes at 17°C and the supernatant rich of fats were discarded. The whey samples 
were diluted 1:50 in Diluent Buffer. 
 
2.2.6 Quantification of AGP in serum  
Once the cross-reactivity of commercially available assay in buffalo is assessed, the 
concentration of AGP was determined by a radial immunodiffusion assay commercial kit 
(Bovine α1-AGPlate, Tridelta Development Ltd., Kildare, Ireland). Five µl of each test sample 
thought to contain AGP is placed in an individual test well and incubated at 37°C for 48–72 
hours. As the sample diffuses radially from the well into the agar gel plate, a specific precipitin 
reaction occurs between AGP and the specific antiserum to incorporated in the gel. A visible 
precipitin ring is formed. Since the area within this ring is directly proportional to the 
concentration of AGP in the test sample, measurement of the ring's diameter allows 
calculation of that AGP concentration, as compared to the two known standards solutions. 
Diameters were plot on the vertical axis of a semi-logarithmic graph and the AGP 
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concentration on the horizontal axis. From the reference curve, the AGP concentration of each 
test sample may be calculated. 
2.2.7 Statistical analysis 
 
All statistical analyses were computed using PASW 18.0 for Windows (SPSS Inc, USA). The 
comparisons between concentration in serum and milk of SAA between healthy and IMI 
animals were performed using ANOVA test. Significance was assessed for P<0.05 (*) and 
P<0.001 (**).  
Comparison between SCC in healthy and in IMI buffaloes was performed using Mann-Whitney 
test, significance was assessed for P<0.05 (*), P<0.001 (**) and P<0.0001 (***). 
Statistical analysis were also performed to evaluate the correlation between SAA and SCC in 
milk and serum. Descriptive statistics are expressed as the mean ± SD. Normality of data 
distribution was assessed by a Shapiro-Wilk test. Since data was not normally distributed a 
non-parametric Spearman correlation was tested. The threshold for statistical significance was 
considered to be P<0.05 (*). 
 
2.2.8 Determination of primary structure of Ceruloplasmin, Haptoglobin, α1 acid 
glycoprotein, Serum amyloid A and Lipopolysaccharide binding protein 
 
Total RNA was extracted from Water Buffalo liver using the RNeasy MiniKit (Qiagen, Italy) 
according to the manufacturer’s protocol. The reverse transcription (RT) reaction was carried 
out on 1mg RNA using iSCRIPT cDNA SYNTESIS Kit (Bio-Rad, Italy). The cDNA was used as the 
template for the PCR (Eppendorf Mastercycler 1) (Eppendorf, Italy). PCR reactions were 
performed in 10 µl ﬁnal volume under the following condition: 1x  buffer Eppendorf, 1.5 mM 
MgCl2, 0.2 mM of each dNTP, 1mM of each primer and 0.5 unit of Taq Polymerase (Eppendorf, 
Italy). The primers used to amplify the coding sequences of buffalo AGP, SAA, Hp and Cp are 
listed in Table 2.3. PCR was carried out in an Eppendorf thermal cycler (Eppendorf, Italy), using 
the following thermal profile: 94°C for 3 minutes, followed by 40 cycles of 94°C for 30 seconds, 
59-60°C for 30 seconds and 72°C for 45 seconds, and a final extension at 72°C for 10 minutes. 
PCR products were applied on a 1.5% agarose gel electrophoresis and the segments of 
predicted molecular weight obtained were gel-puriﬁed using the QIAquick gel extraction kit 
(Qiagen, Italy) and then were quantiﬁed by NanoDrop 1 ND-1000. The fragments were 
sequenced in both directions. 
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The predicted aminoacid sequence was obtained using the ExPASy proteomic server 
(www.expasy.ch). Interproscan and prosite (www.ebi.ac.uk) analysis was carried out to detect 
post-translational modiﬁcations of the five proteins. 
 
APP Primers Sequences 5’-3’ Annealing temperature 
AGP 
AGP_mono_F1 
AGP_end 
CCAACCTGATGACAGYGGC 
GCACCGAAACAAACTTTATTGATGC 
59 °C 
SAA 
SAA_F1 
SAA_R1 
GGCAGCTCAGCTTCACCAG 
GCTGCCTTCTGAGGACAGAG 
58 °C 
Hp 
Apto_F1 
Apto_R1 
GCTCTTCCAGAGCCAGACAC 
CGAGATGAGGTTATGGTGAG 
58 °C 
Apto_F2 
Apto_R2 
GCAGCTTTCCCTGGCAGG 
CCAGACACATAACCCACACG 
58 °C 
Apto_F3 
Apto_R3 
CCTTCGAAAGACTATGTGGC 
CCACTCCTGTGCAGCTTTCC 
58 °C 
Cp 
Ceru_F1 
Ceru_R1 
GCTGTCGGGGCTCCAAGA 
GCTGTCTTCCTCACCAGG 
60 °C 
Ceru_F2 
Ceru_R2 
GTGCAGCCAGGTGAACAG 
CCAGAAAAAGGCCTGCAAACC 
58 °C 
Ceru_F3 
Ceru_R3 
GCTCAGAACCCTGGGCAATG 
GGGACAGTCCACTCATAGG 
60 °C 
Ceru_F4 
Ceru_R4 
CCTTCAGGCTCCCATGTGGC 
CCACGTCAAAAGTCCCTGC 
58 °C 
Ceru_F5 
Ceru_R6 
CCTGTCAAGAGGAGAAAGG 
GCCATTCCAAAGTAAGCCTTC 
58 °C 
LBP 
LBP_F1 
LBP_R1 
GCGACAGATCCAGCCCAG 
CTCCTGATATGTGCACCTCC 
58 °C 
LBP_F2 
LBP_R2 
GGCTGTCTCCAGCTGCAG 
GGGTACAGTCTGGCTATCC 
58 °C 
LBP_F3 
LBP_R3 
CTTCCGCGCCTTCGTTCC 
CCAGAATCTCGAGGAAAGTGC 
58 °C 
Table 2.3.  primers pairs sequences and thermal profiles used for APPs sequencing. 
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2.3 RESULTS 
2.3.1 Bacteriological procedures 
 
Data from the 34 buffalo with an intramammary infection showed that in 73.5% of cases the 
Coagulase-negative staphylococci were present in the udder, followed by other Streptococcus 
spp (8.8%), Aeromonas viridians (5.9%), Streptococcus uberis (5.9%) and Corynebacterium spp 
(5.9%). 
 
 
2.3.2 Determination of Somatic cells counts (SCC) 
 
The comparison between SCC in healthy buffalo and during intramammary infection was 
assessed. The number of somatic cells increase significantly (P<0.0001) in buffaloes with an 
intramammary infection (Fig. 2.3).  
 
 
Figure 2.3. Graph showing the correlation between Somatic cells and pathological condition in buffalos.  
*** P<0.0001 
 
 
The interaction between the concentrations of SAA in milk (MAA) and in serum with the 
Somatic cell count was not significant. The number of somatic cells is very variable, but in 
general they increase with the lower levels of Serum amyloid A in milk (Fig. 2.4) and in serum 
(Fig. 2.5).  
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Figure 2.4. Graph showing the correlation between Somatic cells and Serum amyloid A in milk.   
  
 
 
 
Figure 2.5. Graph showing the correlation between Somatic cells and Serum amyloid A in serum.   
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2.3.3  Assessment of the cross-reactivity of immunological assays for acute phase 
proteins 
 
The assays used to determine the concentration of SAA and AGP in buffalo serum were based 
on immunological methods, such as ELISA and Radial Immuno Diffusion (RID). As a prerequisite 
for their utilization in buffalo, both of them had to be tested for the cross-reactivity of the anti-
bovine SAA and AGP antibodies included in the kit with buffalo SAA and AGP, respectively. 
Western blotting experiments were therefore carried out to determine whether the speciﬁc 
antibody included in the kit cross-reacted with the respective protein and if the antibodies did 
not cross-react with serum proteins other than those targeted by this experiments. The anti-
bovine AGP antibody included in the kit cross-reacts with a band with a molecular weight of 
42–45 KDa, with an electrophoretical pattern (molecular weight and presence of high 
molecular weight glycoform) consistent with that of bovine AGP (Fig.2.6).  
 
Figure 2.6. Western blot shows the presence of AGP in Bovine serum (Lane 1) and in Buffalo serum (Lane 2). 
 
 
The same experiment was carried out using anti-bovine SAA antibody, using bovine serum as 
positive reference control. Results indicate that also the anti-bovine SAA is speciﬁc for buffalo 
SAA, which bands at a molecular weight of 14 KDa (Fig. 2.7). 
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Figure 2.7. Western blot shows the presence of SAA in Bovine serum and in Buffalo serum. 
 
In conclusion, this series of preliminary experiments demonstrated that the two kits that were 
utilized to determine the concentration of AGP and SAA in buffalo serum can cross-react with 
their respective antigens in buffalo serum. 
 
2.3.4 Acute Phase Protein concentration measurement in serum and milk 
The concentration of AGP and SAA in serum (34 samples) or milk (134 samples) were analyzed 
by established immunologic methods utilized for bovine, after validation of the cross-reactivity 
of the antibodies included in the kit with the buffalo proteins.  
The concentration of serum and milk AGP was under the detection limit of the kit, and was 
therefore undetectable in both healthy and IMI buffaloes. 
SAA cut-off values were assumed to be 4.1 mg/l in serum and 1.4 mg/l in milk as in bovine 
(Gronlund et al., 2003).  
Data collected showed that the concentration of serum SAA was under the detection limit in 
healthy buffalo serum. On the contrary, SAA concentration was raised in serum from all of the 
buffaloes with IMI (17.8 mg/l ± 9.5 s.e., P<0.001) (Table 2.4, Fig. 2.8).  
 
Group N Median 25% 75% 
Healthy 26 -14,102 -19,028 -8,734 
IMI 8  45,604 9,060 847,883 
Table 2.4.  SAA concentration (mg/l) in 26 serum from healthy buffaloes and 8 IMI buffaloes.  
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Figure 2.8.  SAA concentration (mg/l) in serum samples. Minimum value,  25% value, Median value,  75% 
value and  Maximum value. ** P<0.001 
 
Results in milk showed that in healthy buffaloes the protein was not detectable, but when IMI 
is present SAA was detectable in all samples with mean concentration of 4.1 mg/l ± 0.37 s.e. 
(p<0.001) (Table 2.5, Fig. 2.9). 
  
Group N Median 25% 75% 
Healthy 91 -0,0750 -0,260 0,250 
IMI 43 3,386 2,231 5,369 
Table 2.5.  SAA concentration (mg/l) in 91 milk samples from healthy buffaloes and 43 from IMI buffaloes. 
 
 
Figure 2.9.  SAA concentration (mg/l) in milk samples. Minimum value,  25% value, Median value,  75% 
value and  Maximum value. ** P<0.001 
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2.3.5 Acute Phase Protein sequencing 
In this study we determined the sequences of Haptoglobin (Hp), Serum amyloid A (SAA), α1-
acid glicoprotein (AGP), Ceruloplasim (Cp) and Lypolisaccaride binding protein (LBP) in water 
buffaloes (Bubalus bubalis). The nucleotide sequences of Hp, SAA, AGP, Cp and LBP were 
determined by cDNA sequencing and showed homology of 96%, 91%, 95%, 98% and 97% 
respectively with bovine one. 
The cDNA sequences of Hp, SAA, AGP, Cp and LBP obtained from buffalo liver have been 
deposited in NCBI GenBank under the accession number of FN600415, FN599527, FN645647, 
FN649762 and FN645646, respectively. 
Their corresponding polypeptide backbones are shown in figure 2.10 in which also presents 
homology comparisons between buffalo and bovine sequenced so far, as well as the 
description of post-translational modiﬁcations. 
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Figure 2.10.  alignment of APPs primary structure, in red site of glycosilation. 
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2.4  DISCUSSION 
 
The acute phase proteins are non-specific markers of inflammation, their serum concentration 
increasing in response to infections and inflammatory conditions. For them to be used as 
specific indicators of mastitis it is therefore essential that they accumulate in milk only during 
episodes of mammary inflammation. The results of this study showed that the concentration 
of serum amyloid A in serum and in milk in buffalo with intramammary infection were higher 
than in healthy animals. An inflammatory stimulus thus seems to be required for the 
concentration of SAA to be increased. On the contrary, the concentration of α1-acid 
glycoprotein was not apparently modified, since the concentration of the protein was under 
the limit of detection of the Radial Immuno Diffusion (RID) kit in both healthy and IMI 
buffaloes. While the concentration in milk of AGP could be assessed only after a concentration 
step relying on an anionic exchange cromathography enrichment (Ceciliani et al., 2005), its 
measurement in milk is challenging. In blood serum on the contray, AGP concentration can be 
easily evaluated following RID assays, since its amount ranged from 100 to 300 µg/ml. Previous 
studies have reported increases in levels of AGP in a variety of inflammatory conditions 
(Sheldon et al., 2001; Motoi et al., 1992) and also AGP is a clinically important acute phase 
protein in cattle and has been used to monitor the inflammatory process (Conner et al., 1988; 
Eckersall et al., 2001, Itoh et al., 1990) including  water buffalo diseases (Horadagoda et al., 
2001; 2002) . 
The higher concentration of acute phase proteins in the milk from infected quarters could be 
due to either to their production within the gland or to their leakage across the blood-milk 
barrier as a result of its disruption by the inflammation, or to a combination of these 
mechanisms. It has been shown that the permeability of the blood-milk barrier increases 
during episodes of mastitis allowing serum proteins to gain access to the milk (Shuster et al., 
1997). However, the demonstration of serum amyloid A gene expression at several extra-
hepatic sites and of several cell types that can synthesise the protein (Marhaug et al., 1997; 
Vreugdenhil et al., 1999), together with the recent identification of a unique isoform of the 
protein in normal bovine colostrums (McDonald et al., 2001), suggests that serum amyloid A 
may be synthesised locally during episodes of mastitis. In this study the correlation between 
the presence of an inflammatory condition in the mammary gland and the raised levels of milk 
and serum SAA have been reported in water buffalo for the first time.  
 
The finding of SAA as a possible marker of mastitis in water buffalo is remarkable. Few 
information is available for what concern water buffalo mastitis diagnosis. While the commons 
 - 54 - 
 
parameters utilized for bovine mastitis diagnosis are also applied to water buffalo milk quality 
definition, in fact it is well known that the relationshipe between Somatic Cell Count and the 
presence of an intrammary infection is regarded as poor in water buffaloes. 
In fact, the data presented in this thesis revealed that the correlation between the SCC and the 
presence of pathogens is poor, whereas the high concentration of SAA can better define the 
presence of IMI. 
 
In conclusion, the present results confirm the importance of APP as diagnostic markers of 
mastitis, even relative to the use of the MAA assay as a biochemical modification of the SAA 
assay. Although MAA and SAA determinations require an ELISA method that is carried out 
routinely only in reference laboratories, MAA could be considered a more reliable marker than 
SCC. The random measurement of this APP in milk samples could allow the identification of 
subclinical mastitis in equal or higher measure than currently obtained with SCC. The use of 
MAA/SAA as markers of the acute phase seems to give a statistically better response than the 
loss of correlation between acute phase proteins and SCC, correlation present in cattle where 
can be used as an indicator of clinical and subclinical mastistis (Gerardi et al., 2009; O’Mahony 
et al., 2006). 
Moreover, systematic control of MAA and SAA on farms could reduce both the laboratory 
costs and the time required for milk analysis. Lastly, as the actual methods for MAA and SAA 
analysis are not suitable for online measurements during milking, it is necessary to develop 
and implement biosensors to be used with automated milking systems, to enable early 
detection of mastitis, to reduce both the treatment time and the economic impact, and to 
improve the health and welfare of animals. 
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Chapter 3 
 
Study on the possible presence of amyloid (AA) in dairy products 
 
3.1  INTRODUCTION 
 
3.1.1 Conformational diseases and Amyloidosis 
 
The amyloidoses constitute a large group of diseases where misfolding of extracellular protein 
fulfils a prominent role. This dynamic process, which occurs in parallel with or as an alternative 
to physiologic folding, generates insoluble, toxic protein aggregates that are deposited in 
tissues in bundles of β-sheet fibrillar protein. Isolation of the protein components of natural 
amyloid and the chemical characterization of these components are indispensable 
investigative tools. To date, at least 21 different proteins have been recognized as causative 
agents of amyloid diseases (Table 3.1). The essence of amyloidosis lies in the capacity of these 
proteins to acquire more than one conformation, a feature that has earned them the 
sobriquet of chameleon proteins. 
AMYLOID 
PROTEIN 
PRECURSOR DISTRIBUTION TYPE SYNDROME OR INVOLVED TISSUES 
Aβ Aβ protein 
precursor 
Localized 
Localized 
Acquired 
Hereditary 
Sporadic Alzheimer’s disease, aging 
Prototypical hereditary cerebral 
amyloid angiopathy 
APrP Prion protein Localized 
Localized 
Acquired 
Hereditary 
Sporadic CJD, new variant CJD 
Familial CJD, GSSD, FFI 
ABri ABri protein 
precursor 
Localized or 
systemic? 
Hereditary British familial dementia 
ACys Cystatin C Systemic Hereditary Icelanding hereditary cerebral 
amyloid angiopathy 
Aβ2M Beta2-microglobulin Systemic Acquired Chronic hemodialysis 
AL Immunoglobulin 
light chain 
Systemic or 
localized 
Acquired Primary Amyloidosis, myeloma-
associated 
AA Serum amyloid A Systemic Acquired Secondary Amyloidosis, reactive to 
chronic infection or inflammation 
including hereditary periodic fever 
ATTR Transthyretin Systemic 
Systemic 
Hereditary 
Acquired 
Prototypical FAP 
Senile heart, vessels 
AApoAI Apolipoprotein A-I Systemic Hereditary Liver, kidney, heart 
AApoAII Apolipoprotein A-II Systemic Hereditary Kidney, heart 
AGel Gelsonin  Systemic  Hereditary  Finnish hereditary amyloidosis 
ALys Lysozyme  Systemic  Hereditary  Liver, kidney, spleen 
AFib Fibrinogen Aα chain Systemic  Hereditary  Kidney  
Table 3.1. Amyloid proteins and their precursors. CJD Creutzfeldt-Jakob disease, GSSD Gerstmann-Sträussler-
Scheinker disease, FFI Fatal familial insomnia, FAP Familial amyloidotic polyneuropathy (modified from Westermark 
et al. 2002). 
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Virchow (1854) coined the name “amyloid” for the pathological extracellular material he found 
during histopathological examination of human patients, since it was thought to be cellulose. 
He used the word, amyloid, because of iodine staining similarities with extracellular plant 
material as wood and starch. In 1859 Friedreich and Kekulé described the proteic nature of 
amyloid. Chemical investigations in the second half of the twentieth century revealed a role for 
glycosaminoglycans and heparan sulphate (Snow et al., 1987; 1995) and chondroitin sulphate-
containing proteoglycans in amyloid (Niewold et al., 1991). A burst in amyloid research 
developed after the electron microscopical discovery of amyloid fibrils in 1959 by Cohen 
(Cohen & Calkins, 1959) and subsequent description by others (Spiro, 1959). It offered new 
possibilities for isolation (Pras et al., 1968), peptide separation and analysis of a large series of 
different chemical amyloid types corresponding to the known variations in clinicopathological 
patterns. Amyloidosis is associated with a wide range of medical disorders, including cancer, 
rheumatoid arthritis, Alzheimer’s disease, chronic renal dialysis, familial amyloid 
polyneuropathy and diabetes, but it can also occur on the absence of pathologies (Sipe, 2004). 
Amyloidosis is characterized by deposition of insoluble fibrils with the β-sheet conformation in 
the extracellular spaces of organs. These insoluble amyloid fibrils, derived from polymerization 
of normally soluble protein precursors, are rigid, fine, nonbranching, 8 to 10 nm in width and 
indeterminate in length (Merlini & Bellotti, 2003). Amyloid fibril deposition can be systemic, 
involving multiple organs of the body or localized to a single organ such as the pancreas in 
diabetes or the brain in Alzheimer's disease. In  general, amyloid  fibril  precursors (monomers) 
are small polyanionic proteins, ranging from 3 to 30 KDa, with a high content of glutamic and 
aspartic acid residues and serine. Once deposited in tissues, the fibril precursor proteins are 
resistant to proteolytic digestion (Husebekk et al., 1991) and are insoluble under physiologic 
conditions (Glenner et al., 1968). In the fibrillar form, amyloid proteins are invariably 
associated with extracellular matrix constituents, including amyloid-P component, 
glycosaminoglycans, fibronectin and other basement membrane or connective tissue 
components. 
The conversion of the structure of the native protein into a predominantly antiparallel β-sheet 
secondary structure (where the N- and C-terminals are oriented in opposite directions) is a 
pathologic process closely related to physiologic protein folding. The folding of a newly 
synthesized polypeptide occurs in a rapid sequence of conformational modifications in the 
cytoplasm. According to the “folding energy landscape theory,” the process follows a funnel-
like pathway in which the conformational intermediates progressively merge into a final 
species (Dobson et al., 1999). In addition, at a minimum of energy similar to that reached by 
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the native protein, the polypeptide can acquire an alternative and relatively stable “misfolded 
state” (Schultz, 2000), which is prone to aggregation. Once the folding process has been 
completed and the native protein secreted (Fig 3.1), many proteins are in dynamic equilibrium 
with a partially folded conformation, and in this state, they retrace the final part of the folding 
pathway, ultimately forming either a native or misfolded protein. In amyloid disease, 
potentially pathogenic misfolded proteins can form in different ways. The protein may have an 
intrinsic propensity to assume a pathologic conformation, which becomes evident with aging 
(e.g., normal transthyretin in patients with senile systemic amyloidosis) (Saraiva, 2001) or at 
persistently high concentrations in serum (e.g., β2-micro-globulin in patients undergoing long-
term haemodialysis) (Verdone et al., 2002). Another mechanism is the replacement of a single 
amino acid in the protein, as occurs in hereditary amyloidosis (Buxbaum et al., 2000). A third 
mechanism is proteolytic remodelling of the protein precursor, as in the case of β-amyloid 
precursor protein (APP) in Alzheimer’s disease (Hardy & Selkoe, 2002). These mechanisms can 
act independently or in association with one another. In addition to the intrinsic amyloidogenic 
potential of the pathogenic protein, other factors may act synergistically in amyloid deposition. 
For example, the protein precursor must reach a critical local concentration to trigger fibril 
formation, a process enhanced by local environmental factors and by interactions with 
extracellular matrixes (McLaurin et al., 2000). 
Figure 3.1. The chains undergo synthesis in the endoplasmic reticulum, fold, pass through the cellular quality-
control mechanism, and are secreted. In the extracellular environment, the mutants may change from a fully folded 
to a partially folded state and then retrace the final part of the folding pathway. Normal proteins are functionally 
active and are normally metabolized. The partially folded polypeptides can generate misfolded molecules, which 
have a high propensity to self-aggregate. Environmental conditions, chemical modifications, and common 
constituents favour the pathologic pathway. Oligomers, or protofibrils, may mediate cellular toxicity through a 
mechanism that activates apoptosis in cells of the target tissues. (Merlini & Bellotti, 2003). 
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Microscopically, routine stains reveal amorphous, acellular, hyaline, eosinophlic extracellular 
material. With special stains as Congo Red, amyloid is salmon-pink, and characteristic yellow-
green birefringence may be seen using polarized light. The organs commonly affected are: 
 
a. Kidneys 
 
Kidneys are classically enlarged, pale grey, waxy and firm. In advanced disease, chronic 
vascular occlusion may result in a shrunken, contracted organ. Amyloid deposit in several area 
such as glomeruli, peritubular regions and blood vessels. 
  
b. Spleen  
 
spleen may be enlarged and amyloid deposits begin between cells. With time two patters 
emerge, sago spleen, in which deposits are limit to splenic follicles, giving rise to tapioca-
similar granules, or lardaceous spleen where amyloid spares also in red pulp. 
 
c. Liver 
 
Amyloid induces hepatomegaly with a pale, waxy gray, firm appearance. Amyloid deposit first 
in the space of Disse, gradually encroaching on parenchyma and sinusoids to produce atrophy 
with massive hepatic replacement. 
 
d. Heart  
Focal amyloid accumulations are minute and typically atrial, vascular or  subepicardial localized 
as pink-gray subendocardial droplets. Microscopically there are interstitial and perimyocyte 
deposits progressively leading to pressure atrophy.  
 
 
3.1.2 Systemic amyloidosis 
 
a. Immunoglobulin light chain (AL)  
 
The first amyloid fibril proteins to be characterized by amino acid sequence analysis were from 
patients with AL amyloidosis, an uncommon disease in which plasma cell dyscrasias result in 
monoclonal light chain production (Glenner et al., 1970). Both intact and amino-terminal 
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fragments of monoclonal immunoglobulin light chains have been found to infiltrate heart, 
kidneys, liver, and spleen and other organs of AL patients (Glenner et al., 1980; Cohen, 1967). 
AL fibrils are usually deposited systemically, but localized deposits are occasionally observed in 
lung and skin (Page et al., 1972; Husby et al., 1981). AL fibrils are usually considered to be 
degradation products of intact light chains. However, it is also possible that AL fibril proteins 
originate as independently synthesized light chain fragment (Buxbaum et al., 1991). The 
underlying causes of AL amyloidosis apparently involve, in addition to the formation of a 
monoclonal popuIation of fragmented or truncated immunoglobulin chains, specific amino  
acid  sequences in the light chain variable region that predispose adoption of secondary and 
tertiary structures necessary for polymerization into fibrils (Solomon et al., 1982).  
 
b. Serum amyloid A (AA)  
 
Two main mechanisms of AA amyloidogenesis are commonly suggested. Both propose that AA 
protein is a split product of SAA. According to one, SAA is cleaved enzymatically to form AA, 
which in turn is deposited in tissues. Alternatively, intact SAA is first precipitated in tissues and 
then is processed enzymatically to form AA. These hypotheses are supported by the following 
evidence: amyloidosis is often correlated with substantial increase in SAA level (DeBeer et al., 
1982). Incubation of SAA proteins with monocytes, macrophages, and even erythrocytes led to 
the production of AA protein, probably by proteolytic enzymes released from these cells or by 
membrane-associated proteases (Shainkin-Kestenbaum et al., 1982; Kedar et al., 1982). 
Administration of human or mouse labelled SAA to mice resulted in deposition of the labelled 
SAA or their intermediates in amyloid fibrils (Husebekk et al., 1985). The immunochemical and 
immunohistochemical studies point to the presence of intact or partially degraded SAA along 
with protein AA in amyloid deposits (Yakar et al., 1994). These studies suggest that AA protein 
is an intermediate fragment in the catabolism of SAA. However, the proteolytic cleavage 
hypotheses are still not certain. Despite extensive efforts, proteolysis of SAA to AA has not 
been demonstrated directly by in vivo study. In addition, amyloidosis usually occurs only in low 
incidence among patients suffering from amyloid-inducing diseases, despite the presence of 
chronically elevated SAA concentrations in most patients (McAdam et al., 1982; Husby, 1985). 
In mice, despite similar solubility or accessibility of SAA1 and SAA2 to proteolytic enzymes, 
only SAA2 is structurally related to AA protein (Hoffman et al., 1984). Therefore, additional 
factors or different mechanisms must be operating in the formation of amyloid. Some of the 
answers to the question of amyloidogenesis raised above may lie in the interaction between 
SAA and other constituents of the amyloid fibrils.  
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In summary, the SAAs are a family of apolipoproteins, increasing to substantial quantities 
during inflammation, chronic infection, and certain malignancies. This elevation may be 
followed by the development of AA amyloidosis. The AA protein is thought to be a split 
product of SAA. However, until the precise metabolic pathway leading to AA formation is 
disclosed, current concepts of AA amyloidogenesis should be considered hypothetical. 
 
c. Transthyretin (ATTR) 
 
Transthyretin is a 55 KDa non-glycosilated plasma protein originally called Prealbumin because 
of its electrophoretic migration ahead of albumin; the molecule was later renamed 
transthyretin because of its function as a carrier for the thyroid hormones (Blake, 1981; 
Cornwell et al., 1987; Saraiva et al., 1993). TTR also serves as a carrier for the retinol binding 
protein complex (Smith et al., 1971). More than 35 TTR variants have been identified by 
protein and DNA screening studies and they exhibit clinically heterogeneous amyloidosis 
(Saraiva et al., 1992; Jacobson et al., 1991; Cohen et al., 1994). X-ray diffraction studies of TTR 
amyloid (ATTR) fibrils showed a mutation in val  met at 30 TTR monomers that permit the 
formation of intersubunits disulfide bonds between the single cysteine facilitating 
polymerization into fibrils (Wahlquist et al., 1991; MIgita et al., 1991). Fibrils are made up of 
both full-length TTR and fragments of TTR monomers and of variable quantities of both mutant 
and normal TTRs (Felding et al., 1985). The pathogenesis of ATTR differs from AL and AA 
amyloidosis in that the ATTR fibril precursor is a constitutive protein present in plasma at 
concentrations of about 100-400µg/ml from birth, whereas both AL and AA require specific 
pathological events to stimulate precursors synthesis.  
 
d. Apolipoprotein AI (AApoAI) 
 
Apolipoprotein AI-derived (AApoAI) amyloidosis can be present as a non-hereditary form with 
wild-type protein deposits in atherosclerotic plaques, or as a hereditary form with the variant 
protein depositing more systemically. The clinical manifestations of hereditary AApoAI 
amyloidosis frequently involve liver, kidney, larynx, skin, and myocardium. In rarer cases, 
amyloid is also found in the testes and adrenal glands (Obici et al., 2006). ApoAI is a plasma 
protein of 28 KDa synthesized by the liver and the small intestine. It is the main protein of 
high-density lipoprotein particles and important for the formation and metabolism of high-
density lipoprotein cholesterol esters (Sorci-Thomas et al., 2002). Mature apoAI consist of 243 
amino acids encoded by exons 3 and 4 of the APOA1 gene (Karathanasis et al., 1983). More 
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than 50 apoAI variants have been described (Obici et al., 2006), and about half of them are 
associated with a decreased plasma level of high-density lipoprotein-apoAI.  
 
3.1.3 Amyloidosis in cattle 
 
Bovine Amyloidosis belongs to the same group of diseases as human systemic reactive AA 
Amyloidosis and is characterized by persistent and intractable diarrhea and systemic edema; a 
rectal examination often confirms nephromegaly. Clinicopathological features include 
nephrotic syndrome-like symptoms, such as severe hypoproteinemia and proteinuria (Johnson 
et al., 1984; Konishi et al., 1975).  
Histopathological analysis reveals severe amyloid deposition in various organs, especially the 
kidney and liver (Murray et al., 1972; Yamada et al., 2006). A kidney biopsy is needed to 
confirm the diagnosis, but as it is difficult to perform this procedure in a clinical setting, some 
cows may die without a diagnosis being made. Moreover, it can be clinically diagnosed only at 
the terminal stage. Epidemiologically the disorder is more common in aged cows or associated 
with chronic inﬂammatory diseases of the mammary gland, joints, and respiratory system 
(Gruys, 2004; Yakar et al., 1995). Bacterial infections usually lead to a strong systemic acute 
phase response (APR) (Alsemgeest et al., 1994); because of the strong reaction of 
mononuclear/phagocytic system cells to viral infections, APR is generally milder in viral 
infections (Alsemgeest et al., 1995; Nakayama et al., 1993).   
 
3.1.4 Transmissibility of systemic amyloidosis 
 
Certain aspects of animal models of the Amyloidosis caused by serum amyloid A (Lundmark et 
al., 2002) and apolipoprotein A-II (Higuchi et al., 1999) have introduced the possibility that 
amyloidosis is transmissible. In mice, amyloid protein A amyloidosis (AA) is caused by an 
inflammatory reaction that results in overproduction of the acute phase protein serum 
amyloid A. Injection or oral administration of amyloid-enhancing factor, a crude homogenate 
of natural amyloid fibrils, accelerates the deposition of amyloid during the inflammatory 
process (Lundmark et al., 2002; Elliott-Bryant et al., 1998). These findings are consistent with 
the capacity of fibrillar seeds to catalyze conformational changes in the soluble protein. The 
capacity of preformed fibrils to trigger fibrillogenesis has been demonstrated in vitro for 
amyloid β (Aβ) peptides (Jarrett et al., 1993), lysozyme (Morozova-Roche et al., 2000), and 
beta2-microglobulin (Naiki et al., 1997) (Fig. 3.2).  
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Figure 3.2. Kinetics of Fibril Formation. The blue line indicates the formation of amyloid fibrils, beginning from a 
solution of monomeric proteins, which may temporarily assume an amyloidogenic conformation. Initially, 
conditions do not favour aggregation, and this period corresponds to the lag phase that precedes the formation of 
fibrils. Once a critical nucleus has been generated, the conditions change to favour aggregation with very fast 
kinetics. Any available monomers in the amyloidogenic conformation quickly become entrapped in the fibril. The 
red line represents a similar condition in which preformed fibrils are added, thus making the lag phase much 
shorter. 
 
With the exception of prion diseases, there is no evidence that amyloidosis is transmissible in 
humans. However, the formation of amyloid can be accelerated by the presence of fibril nuclei 
in tissues. In 1957 a strange phenomenon was described in experimental mouse AA 
amyloidosis, in fact many strains of mice develop a form of systemic amyloidosis when given a 
chronic inflammatory challenge. The ﬁnding that formation of amyloid ﬁbrils is a nucleation 
dependent event is of fundamental importance and this seems to be principally the same for 
all forms of amyloid including that of the prion protein (Jarrett & Lansbury, 1993). In a solution 
of an amyloid ﬁbril protein above the critical concentration a nucleus forms after a lag phase 
which can be quite long. Seeding such a solution with preformed ﬁbrils of the same nature 
more or less abolishes this lag phase (Jarrett & Lansbury, 1993). In some yet unknown way, the 
misfolded and aggregated protein induces a rapid misfolding and aggregation of the protein in 
solution (Fig. 3.3). 
 
Figure 3.3. Mechanism of fibrils formation by nucleation. 
 
Prion disorders are transmissible by different routes, including the oral way, most dramatically 
shown by the example of kuru (Gajdusek et al., 1966; Collinge et al., 2006). In most 
experiments, the infectious material has been given intravenously or intraperitoneally. 
However, addition of a small amount (about 1 mg/l; calculated total dose per mouse 0.2 mg) 
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of a ﬁbril preparation to the drinking water for 5 weeks before induction of inﬂammation 
accelerated the development of AA-amyloidosis (Lundmark et al., 2002). Where and how the 
seeding AA-amyloid ﬁbril or particle is taken up from the gastrointestinal tract is completely 
unknown. Also the route for the infectious AA-material to the spleen has not yet been clariﬁed 
(Johan et al., 1998; Cohen & Cathcart, 1972). Further spreading can take place by the blood 
since in murine AA-amyloidosis, some circulating monocytes were found to carry amyloid 
ﬁbrils and had the capability to accelerate amyloidosis in recipient animals (Sponarova et al., 
2008). Prion diseases can be transmitted between species, a well-known fact since the work by 
Gajdusek et al. (1966) but particularly since the occurrence of human variant spongiform 
encephalopathy (variant Creutzfeldt-Jakob disease) (Collinge, 1999) originating from cattle and 
transmissible to mice (Wadsworth et al., 2008). Given the resemblance of prion protein with 
other amyloid ﬁbril proteins’ behaviour in vitro (Rochet & Lansbury, 2000), it is natural to 
question if AA-amyloidosis is transmissible between species. In 1969, Shirahama et al. reported 
transfer of experimental amyloidosis by human splenic amyloid homogenate to mice 
(Shirahama et al., 1969). In more extensive studies, AA-amyloid ﬁbrils from several different 
mammalian (mouse, cow, cheetah and cat) and one avian species were found to accelerate 
experimental murine amyloidosis (Liu et al., 2007; Cui et al., 2008). Westermark et al. (2009) 
found a considerable difference in “infectivity” between donor species and while AA-ﬁbrils 
extracted from donkey were efficient as amyloid enhancers, human AA-ﬁbrils were not. Cui et 
al. (2008) found that bovine AA-ﬁbrils have the ability to induce AA-amyloidosis in mice. 
However, ﬁbrils from none of the other tested species were as efficient as those of mice in 
agreement of a species barrier, similar to that described for prions (Scott et al., 2008).  
Another possible route of transmission of AA-amyloidosis could be by heterologous seeding. 
Systemic amyloidosis is common in many mammalian and avian species and may enter our 
food chain. Tojo et al. found a high incidence of AA-amyloidosis in slaughtered Japanese cows 
(Tojo et al., 2005). This form of amyloidosis is particularly common in several species of birds 
and is a problem in duck and goose industry. AA-amyloid was found in commercially available 
duck liver and in paté de foie gras and ﬁbrils from such material accelerated amyloidosis in 
mice over-expressing IL-6, both when administered intravenously and given orally (Solomon et 
al., 2007). Similar to the situation with bovine spongiform encephalopathy where a large 
human population is believed to have ingested infected meat from such animals, it is very 
likely that many, perhaps a majority of individuals in many countries have eaten food 
containing AA-amyloid ﬁbrils which may, if the conditions are the right, induce amyloidosis in 
the recipient. 
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Korenaga et al. (2006) demonstrated a vertical transmission of AA-amyloidosis from female 
mice inoculated with amyloid fibrils to their offspring in which the amyloid deposition in 
intestine is significantly accelerated. It was also shown that the transmission via milk from mice 
to their offspring is possible. As shown by Eckersall et al. (2006) SAA is an acute phase protein 
which increases its levels in cattle serum and also in milk during inflammation. The presence of 
a pathological status in the bovine mammary gland should facilitate the induction of unfolding 
of protein which led to the starting of a process of conformational shifting into β-sheet. One of 
the characteristics of fibrils is the difficult inactivation by physical or chemical methods (Zhang 
et al., 2006), for this reason the purpose of this first study is the evaluation of the possible 
degradation of fibrils by proteolysis during processing of milk in cheese making procedures.  
 
The aim of this study was to explore the possibility that, give the high concentration of SAA in 
milk, there is a possibility that 
a) the milk SAA may be converted in AA fibrils by the ripening procedure utilized in 
cheese making and 
b) the same ripening procedure may induce the formation of amyloid fibrils, which are 
considered to be potentially dangerous for human safety. 
Models for neither in vivo nor in vitro amyloid fibril formation in milk is available so far. It is 
therefore not possible to verify the spontaneous or induced precipitation of SAA in AA fibrils in 
milk. 
Therefore, we decided to purify amyloid fibrils from spleen and to add them to crude milk, at a 
concentration similar to that found in bovine mastitis.  
The experimental hypothesis that we verified was that serum amyloid A fibrils added to crude 
milk before ripening are not destroyed by the enzymes commonly utilized for cheese making, 
and therefore they may possibly represent a possible treath for human safety, on the 
background of the oral transmission of amyloidosis in mice.  
In order to verify this hypothesis, we 
a)  set  a protocol of extraction of serum amyloid A fibrils from bovine tissues, and 
b) apply a commercial ELISA kit used for SAA quantification in serum to quantify the fibrils 
obtained from tissues.  
Then we 
c) added amyloid fibrils to crude milk at a concentration similar to that of SAA during 
mastitis and induced an experimental caseification 
d) finally, the possible presence of amyloid fibrils in cheese was determined by Western 
Blotting using specific anti-SAA bovine antibodies.  
 - 65 - 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Samples and histological diagnoses of amyloidosis  
 
Spleen and kidney from adult cows were collected in a local abattoir and stored at -80°C until 
use. Macroscopically amyloidotic organs were selected using the following criteria: increased 
dimensions and pale gray colour. Diagnosis for amyloidosis was definitely confirmed by 
histology. Fragment of tissues were directly frozen in liquid nitrogen and then cryosections of 
5µm were prepared on positive charged slides. Section were fixed with frozen acetone for 3 
minutes and stored at -20°C until use. Before staining sections were warmed at room 
temperature, then were re-hydrated using a sequence of decrescent ethanol concentration 
(100%, 90%, 70% 50%) and distilled water. The slides were stained in Hematoxilin for 10 
minutes and after washing in distilled water, they were incubated in Congo Red for 1 hour. 
Finally sections were dehydrated rapidly in absolute alcohol, cleared in xylene and mounted.  
  
 
3.2.2 AA fibrils purification 
 
Fibrils were isolated from 14g of spleen tissue by the classical water extraction procedure (Pras 
et al. 1968; Mangione et al. 2001) in the presence of 1.5 mM phenylmethylsulfonyl fluoride 
(PMSF) after repeated homogenization in TE Buffer pH8 containing 10mM Tris/EDTA, 140mM 
NaCl, 0.1%NaN3, 1.5mM PMSF in ice and centrifugation at 40000 rpm in ultracentrifuge for 35 
minutes at 4°C. When the supernantant became clear the TE Buffer was substitute with 
distilled water containing 1.5mM PMSF and the cycles of homogenization and centrifugation 
were repeated 9 times. All the water extraction fractions were lyophilized and used for further 
studies. Part of the pellet and aliquot of extraction fraction were stained with Congo Red.  
 
 
3.2.3 Quantification of fibrils 
 
The extraction fractions were resuspended in 4ml of distilled water and quantified using a 
commercial  solid phase sandwich Enzyme Linked Immuno Sorbent Assay (ELISA) kit (Phase 
Range Serum Amyloid A Assay Tridelta Dev. Ltd, Ireland) commonly used for quantification of 
serum SAA. Each sample was diluted in Dilution Buffer 1X (1:500) in a final volume of 50µl and 
was added to 50µl of a SAA specific biotinilated monoclonal antibody (1:100) for 1 hour at 
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37°C. Each sample was analyzed in duplicate. The plate was then washed three times with 
Washing Buffer, and then incubated with 100µl of Streptavidin-Peroxidase (HRP) (1:4000) for 
30 minutes, at room temperature in the dark. The plate was washed three times and then 
incubated with 100µl of 3,3',5,5' tetramethyl-Benzidine (TMB) for 30 minutes at room 
temperature. Finally the reaction was stopped adding 50µl of Stop solution and the 
absorbance was read in a spectrophotometer at 450nm.  
The mean absorbance for each sample, or standard was calculated. The absorbance of the 
standards was plot against the standard concentration and the best smooth curve through 
these points was drawn to construct the standard curve. The concentrations of the test 
samples and controls were calculated from the standard curve by multiplying the interpolated 
value by the appropriate dilution factor. 
 
 
3.2.4 SDS-PAGE, Western Blotting and Coomassie Brilliant Blue Staining 
 
The extraction fractions were separated by SDS-PAGE electrophoresis on 12% acrylamide gel. 
The homogeneity of purified fibrils was confirmed by Congo red stain of aliquots of pellet 
resuspended in distilled water and supernatants. Fibrils were then Western-blotted onto a 
nitrocellulose membrane. Membrane was blocked for 1 hour at room temperature with 
Phosphate Buffered Saline (PBS) with 2% Bovine Serum Albumin (BSA). After three wash with 
PBS with 0.2% Tween-20 (PBST) the membrane was incubated with SAA specific biotinilated 
monoclonal antibody (1:200) (Tridelta Dev. Ltd, Ireland) for 14 hours at 4°C. The membrane 
was then washed three times in PBST and then incubated with Vectastain ABC Elite standard 
kit (VectorLab, UK) for 5 minutes with a final wash in PBST. 
Using the same conditions another SDS-PAGE electrophoresis has been performed. The gel 
was stained for 20 minutes with a solution of Coomassie Brilliant Blue (40% methanol, 10% 
acetic acid, 0.025% Coomassie Brilliant Blue R-250 ). Then it was destained with a solution 
containing 40% methanol and 10% glacial acetic acid until background of the gel is fully 
destained. 
 
3.2.5 Experimental cheese making  
 
The experimental cheeses were made from whole, raw milk (un-pasteurized milk). The milk 
was purchased from a local market. Raw milk (500ml) was heated up to 35°C in agitation. To 
one of the milk amyloid fibrils of bovine origin previously extracted in concentration of 
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20µg/ml were added. Liquid rennet extract of bovine origin (1-3 ml/l) was used and left resting 
for 1 hour. The coagulum was cut with miniature stainless-steel tools and was placed in sterile 
boxes fitted with a grid to facilitate whey draining. One of the cheeses was inoculated with 
amyloid fibrils of bovine origin previously extracted in concentration of 20µg/ml. The two kind 
of cheese were stored at 4°C for 10 days. At the end of seasoning the cheese was cut in pieces 
and store at -80°C for the following analysis. Cheese without fibrils was called “control” and 
cheese with fibrils was called “treated”. 
 
 
3.2.6 Extraction of fibrils from cheese 
 
Fibrils were isolated from 20g of control and treated cheese by the classical water extraction 
procedure used for isolation from tissues and described above. All the water extraction 
fractions were lyophilized and used for further studies. Part of the pellets was stained with 
Congo Red.  
 
 
3.2.7 SDS-PAGE and Western Blotting 
 
The extraction fractions were separated by SDS-PAGE electrophoresis on 12% acrylamide gel. 
Fibrils were then transferred to a nitrocellulose membrane. Membrane was blocked for 1 hour 
at room temperature with Phosphate Buffered Saline (PBS) with 2% Bovine Serum Albumin 
(BSA). After three wash with PBS with 0.2% Tween-20 (PBST) the membrane was incubated 
with a mouse anti-bovine SAA specific policlonal primary antibody (1:100) (kindly gifted by 
dr.McDonald) for 1 hour at room temperature. The membrane was then washed three times in 
PBST and incubated 45 minutes with a goat anti-mouse IgG peroxidase conjugated secondary 
antibody (1:2000). Detection was carried out by enhanced chemiluminescence (ECL) using 
ImmobilonTM Western Chemiluminescence HRP Substrate (Millipore, Italy).  
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3.3 RESULTS 
 
3.3.1  Morphology and histology of bovine spleen and kidney  
 
The macroscopical analysis of the organs collected at slaughterhouse confirm the presence of 
amyloid deposition, kidneys and spleen are enlarged, pale grey, waxy and firm. Microscopically 
amyloid deposition is clearly present in spleen around blood vessels (Fig. 3.4a) and in kidney in 
glomeruli and blood vessels (Fig. 3.4b). 
 
Figure 3.4. Picture showing sections stained with Congo Red and Hematoxilin which shown the amyloid deposits in 
and in the endothelial cells of spleen (a) and in the glomerulus of kidney (b).  
 
 
 
3.3.2 Purification, quantification and analysis of fibrils extracted from tissue 
 
The extraction protocol commonly used for amyloid purification in human tissues was applied 
in bovine and it permits to isolate a good quantity of fibrils from spleen. The presence of 
amyloid fibrils in the purified fraction was assessed by Congo Red staining. These amyloid 
deposits present an orange-red stain in light microscopy (Fig 3.5a) and are identified on the 
basis of their apple-green birefringence under a polarized light microscopy (Fig 3.5b).   
 
 
Figure 3.5. Representative picture of fibrils from water extraction fraction 3. Under light microscope the fibrils 
appear as orange-red aggregates (a) and under polarized light they are characterized by apple-green birefringence 
color (b).  
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The quantification of fibrils from the extraction fraction performed using an ELSIA kit used for 
quantification of SAA in serum showed good results also starting from a suspension. The fibrils 
mean concentration in aqueous fraction is 1.041 µg/ml.  
SDS-PAGE gel electrophoresis and Coomassie Brilliant Blue showed the presence of fibrils 
aggregates of different molecular weight (Fig. 3.6).  
 
 
Figure 3.6. Coomassie Brilliant Blue staining of fibrils from water extraction fractions. The staining shows the 
distribution of fibrils in different molecular weight aggregates. St: standard molecular weight; lane from 1 to 9: 
fibrils from water extraction fractions.  
 
 
The presence of aggregates of SAA fibrils was confirmed by western blot using an antibody 
specific for this protein (Fig. 3.7). 
 
Figure 3.7. Western blot of fibrils purified in water extraction fraction 3 (Lane1) and 4 (Lane2). Bovine serum was 
used as positive control (Lane3).  
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3.3.3 Experimental cheese 
 
The cheese making starting from 500ml of raw milk led to the creation of two different kinds of 
cheeses. As shown in figure 3.8 the two cheeses showed a different colour, the control one is 
white (a) instead of the treated one which showed a yellowish colour (b).  
 
Figure 3.8. Experimental cheeses prepared from raw milk. The two kinds of cheeses showed a different colouring, 
the one without fibrils is white (a) instead of the one with addition of fibrils is yellowish (b). 
 
  
3.3.4 Purification and analysis of fibrils extracted from cheese 
 
The extraction protocol used for amyloid purification in tissues was applied in cheese and it 
permits to isolate a good quantity of fibrils from both control and treated cheeses. The 
presence of amyloid fibrils in the purified fraction was assessed by Congo Red staining. These 
amyloid deposits present an orange-red stain in light microscopy (Fig 3.9a) and identified on 
the basis of their apple-green birefringence under a polarized light microscope (Fig 3.9b).  
 
 
Figure 3.9. Amyloid aggregates preset in pellets from treated cheese showed by orange-red stain in light 
microscope (a) and apple-green birefringence under a polarized light microscope (b).  
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The presence of bovine amyloid fibrils, as well as their electrophoretic pattern, was 
determined by SDS-PAGE followed by Western blotting and immunostaining using an antibody 
specific for this protein in both kinds of cheese (Fig. 3.10). 
 
Figure 3.10. Western blot performed on fibrils purified from experimental cheeses. SAA fibrils are present in control 
and in treated extraction fractions. Bovine liver was used as positive control (+) and SAA protein is identified as 
expected at 14KDa. Lane 1-3: blot of extraction fraction of control cheese. Lanes 4-6: blot of extraction fraction from 
treated cheese. 
 
 
The figure cleary showed that no amyloid protein was present in lanes 1, 2 and 3, where 
samples of cheese prepared with milk without previous adding of fibrils were loaded. On the 
contrary, lanes 4, 5 and 6, which include samples of cheese previously added with amyloid 
fibrils, clearly showed a positive staining at a molecular weight correspondent to SAA, as 
shown in lanes + (positive control form liver). High molecular weight immunoreactive bands 
were also present. 
The results clearly showed that the enzymatic processes triggered for cheese making were not 
able to destroy amyloid fibrils added to milk before ripening. 
 
 
3.4 DISCUSSION 
 
All of diagnostic tools and research that concern amyloidosis start from the characterization of 
the fibrils isolated from tissues of affected patients. For these reasons, we showed in this study 
the isolation of amyloidogenic fibrils from bovine tissues, after the confirmation of the 
pathology by morphological and histological analysis of the considered tissues, i.e. kidney and 
spleen. The purification was obtained by the application of the aqueous extraction protocol 
used in humans (Pras et al., 1968). The same extraction protocol was also applied to isolate 
fibrils from experimental cheese.  
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Furthermore, our study demonstrated that a commercial kit commonly used for quantification 
of SAA in serum could be also applied for the quantification of a suspension of fibrils previously 
purified from tissue and from cheese.  
The antibody used in ELISA and in Western Blot confirm the presence of AA in the extraction 
fraction from tissue and cheese. The data collected from Western Blot compared to the 
Coomassie Brilliant Blue staining showed the presence of aggregates of fibrils at different 
molecular weight. 
As previously reported by some authors amyloid fibrils can resists to physical and chemical 
methods (Zhang et al., 2006), our purpose was to evaluate if the proteolitic activity of rennet 
during cheese making  should destroy the AA fibrils experimentally added to raw milk. The 
fibrils are only in part degraded but we could show that some of them are present after 10 
days of resting. Therefore, our results clearly show that the normal process of ripening is not 
capable to destroy amyloidotic fibrils. 
Some reports showed that amyloid fibrils can be transmitted from a species to another via milk 
(Korenaga et al., 2006), raw tissue homogenates (Zhang et al., 2006), via feces (Zhang et al., 
2008) and also via food, for example in paté de foie gras (Solomon et al., 2007). All these data 
and the confirmation of the presence of fibrils in cheese let us to suggest that cheese may, at 
least theoretically, be included in the aliments “at risk” for oral transmission of amyloidosis. 
Similar to the situation with bovine spongiform encephalopathy, where a large human 
population is believed to have ingested infected meat from such animals, it is very likely that 
many, perhaps a majority of individuals in many countries have eaten food containing AA-
amyloid ﬁbrils which may, if the conditions are the right, induce amyloidosis in the recipient. 
One interesting phenomenon, noted in the mouse, is that there may be a long delay between 
the intake of amyloid enhancing material and the development of disease. When amyloid 
ﬁbrils were given intravenously into animals without an inﬂammatory challenge, the mice 
stayed healthy. However, if inﬂammation was induced amyloidosis developed almost 
immediately. That means the individuals may be primed for the amyloid disease in the case 
that a chronic inﬂammatory disease is acquired later. A similar primed state has been 
described in murine AA-amyloidosis after resolution of the deposits (Hawkins et al., 1990). It 
will be very difficult to prove an association of ingestion of amyloid and development of AA-
amyloidosis if this kind of delayed effect is true also in human.  
 
Several issues remain to be addressed: for example, it is not known if the increase of 
concentration of SAA in milk can induce the precipitation of SAA in AA fibrils. 
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The fibrils were added at a concentration similar to that found in milk during the systemic 
response to inflammation after acute mastitis. From a theoretical point of view, the 
biochemical conditions of the mammary gland environment during acute inflammation, 
including lowering of pH, the presence of high concentration of activated proteases and the 
production of reactive oxygen species, may induce the destabilization of the secondary 
structure of serum amyloid A, and the development of an extracellular unfolded protein 
response. This phenomenom, in turn, may eventually drive the soluble SAA to precipitate in 
un-soluble fibrils. 
It has to be demonstrated whether these pathologic conditions are sufficient to induce the 
generation of AA.  
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Chapter 4 
 
Conclusions & Final Remarks 
 
Amyloidosis in cattle is a disease characterized by Amyloid A protein precipitation in tissues 
such as kidney and spleen as unsoluble fibrils. We demonstrated in our study that AA-fibrils 
can be isolated from tissues using a protocol commonly applied to humans and based on 
aqueous extraction. We also found that the addiction of these fibrils, in a concentration that 
resemble the SAA levels during an acute phase response, in raw milk that undergoes cheese 
making procedures, should make us able to find them after purification from cheese. 
We validated the capability of a commercial ELISA kit, commonly used for serum quantification 
of SAA, to identify and quantify an aqueous suspension of purified fibrils properly diluted. 
It would be interesting to compare the potential transmissibility of fibrils from normal cheese 
and cheese with fibrils added. Future development include the feeding of mice with “infected” 
cheese, in order to verify if this should be potentially pathological and can be the seed of a 
process of endogenous fibrils accumulation. Further study can be done to understand this 
process of transmission.  
  
In water buffalos five of the major bovine acute phase proteins have been sequenced to verify 
if in this species their primary structures are conserved. Our study demonstrated an homology 
of more than 95% of all of this proteins. For this reason we decided to evaluate the potential 
biological role during an intramammary infection. We have chosen two of the main bovine 
acute phase proteins, including AGP and SAA. AGP, remarkably, i.e. the protein that increases 
its concentration during an acute phase response in cattle, is under the detection limit in 
healthy animals but also in buffaloes that showed a intramammary infection, whereas SAA 
concentration in serum and in milk are increased in infected animals in comparison with 
healthy buffaloes. 
For all these reasons we could say that SAA can be used as a marker of pathology in buffaloes. 
Further study should be done to understand if SAA serum concentration can be helpful to 
determine the severity of a mastitis and how its production is modulated during the course of 
the disease. 
Future investigations will verify the possible role of Hp, Cp and LBP as other markers of 
pathology in water buffaloes.   
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